Document and Entity Information
Document and Entity Information | 12 Months Ended |
Dec. 31, 2020shares | |
Document Information [Line Items] | |
Document Type | 20-F |
Document Registration Statement | false |
Document Annual Report | true |
Document Transition Report | false |
Document Shell Company Report | false |
Document Period End Date | Dec. 31, 2020 |
Entity Registrant Name | ARGENX SE |
Entity Common Stock, Shares Outstanding | 47,571,283 |
Entity Well-known Seasoned Issuer | Yes |
Entity Voluntary Filers | No |
Entity Current Reporting Status | Yes |
Entity Interactive Data Current | Yes |
Entity Filer Category | Large Accelerated Filer |
Entity Emerging Growth Company | false |
Entity Shell Company | false |
Entity Central Index Key | 0001697862 |
Current Fiscal Year End Date | --12-31 |
Document Fiscal Year Focus | 2020 |
Document Fiscal Period Focus | FY |
Amendment Flag | false |
ICFR Auditor Attestation Flag | true |
American Depositary Shares [Member] | |
Document Information [Line Items] | |
Title of 12(b) Security | American Depositary Shares, each representing one ordinary share with a nominal value of €0.10 per share |
Trading Symbol | ARGX |
Security Exchange Name | NASDAQ |
Ordinary shares [member] | |
Document Information [Line Items] | |
Title of 12(b) Security | Ordinary shares with a nominal value of €0.10 per share |
Trading Symbol | ARGX |
Security Exchange Name | NASDAQ |
CONSOLIDATED STATEMENTS OF FINA
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION € in Thousands, $ in Millions | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) |
Current assets | |||
Cash and cash equivalents | € 991,609 | € 331,282 | € 281,040 |
Restricted cash — current | 1,692 | ||
Research and development incentive receivables — current | 377 | 261 | 301 |
Financial assets — current | 635,359 | 1,004,539 | 283,529 |
Prepaid expenses | 22,747 | 9,022 | 2,995 |
Inventories | 20,532 | ||
Trade and other receivables | 5,687 | 28,115 | 2,886 |
Total current assets | 1,676,311 | 1,373,219 | 572,443 |
Non-current assets | |||
Other non-current assets | 6,383 | 3,226 | 252 |
Research and development incentive receivables — non-current | 16,840 | 8,566 | 4,883 |
Deferred tax asset | 12,255 | ||
Property, plant and equipment | 9,494 | 8,167 | 824 |
Intangible assets | 136,410 | 40,161 | 56 |
Total non-current assets | 181,382 | 60,120 | 6,015 |
TOTAL ASSETS | 1,857,693 | 1,433,339 | 578,458 |
Equity | |||
Share capital | 4,757 | 4,276 | 3,597 |
Share premium | 2,058,123 | 1,308,539 | 673,454 |
Accumulated losses | (861,491) | (332,568) | (169,603) |
Other reserves | 162,984 | 70,499 | 30,947 |
Total equity | 1,364,373 | 1,050,746 | 538,395 |
Deferred tax liabilities | 1,212 | ||
Provisions for employee benefits | 128 | 64 | 7 |
Lease liabilities- non-current | 5,035 | 4,540 | |
Deferred revenue — non-current | 219,248 | 218,032 | |
Total non-current liabilities | 224,411 | 222,636 | 7 |
Lease liabilities — current | 2,833 | 1,974 | |
Trade and other payables | 224,262 | 85,301 | 37,072 |
Tax liabilities | 2,850 | 344 | 823 |
Deferred revenue - current | 37,754 | 72,338 | 2,161 |
Total current liabilities | 267,699 | 159,957 | 40,056 |
Total liabilities | 492,110 | 382,593 | 40,063 |
TOTAL EQUITY AND LIABILITIES | € 1,857,695 | € 1,433,339 | € 578,458 |
CONSOLIDATED STATEMENTS OF PROF
CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME | |||
Revenue | € 36,425 | € 69,783 | € 21,482 |
Other operating income | 18,109 | 12,801 | 7,749 |
Total operating income | 54,534 | 82,584 | 29,231 |
Research and development expenses | (325,479) | (197,665) | (83,609) |
Selling, general and administrative expenses | (149,367) | (64,569) | (27,471) |
Total operating expenses | (474,846) | (262,234) | (111,080) |
Change in fair value on non-current financial assets | 2,544 | 1,096 | |
Operating loss | (417,769) | (178,554) | (81,849) |
Financial income/(expense) | (1,414) | 14,275 | 3,694 |
Exchange gains/(losses) | (106,956) | 6,066 | 12,308 |
Loss before taxes | (526,139) | (158,213) | (65,847) |
Income tax expense | (2,784) | (4,752) | (794) |
Loss for the year and total comprehensive loss | € (528,923) | € (162,965) | € (66,641) |
Weighted average number of shares outstanding | 45,410,442 | 38,619,121 | 33,419,356 |
Basic and diluted loss per share | € (11.65) | € (4.22) | € (1.99) |
Loss for the year | € (528,923) | € (162,965) | € (66,641) |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS € in Thousands, $ in Millions | 12 Months Ended | ||
Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | |
CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES | |||
Operating result | € (417,769) | € (178,554) | € (81,849) |
Adjustments for non-cash items | |||
Amortization of intangible assets | 215 | 38 | 19 |
Depreciation of property, plant and equipment | 3,214 | 2,128 | 474 |
Provisions for employee benefits | 65 | 57 | (18) |
Expense recognized in respect of share-based payments | 84,479 | 39,552 | 19,183 |
Fair value gains on non-current financial assets at fair value through profit or loss | (2,544) | (1,096) | |
Adjustments for non-cash items | (332,340) | (137,875) | (62,191) |
Movements in current assets/liabilities | |||
(Increase)/decrease in trade and other receivables | 19,767 | (22,965) | (44) |
(Increase)/decrease in inventories | (20,532) | ||
(Increase)/decrease in other current assets | (13,840) | (5,170) | (800) |
Increase/(decrease) in trade and other payables | 45,652 | 47,995 | 21,784 |
Increase/(decrease) in deferred revenue — current | (34,585) | 62,106 | (8,868) |
Movements in non-current assets/liabilities | |||
(Increase)/decrease in other non‑current assets | (8,888) | (5,560) | (1,720) |
Increase/decrease in deferred revenue – non-current | 1,216 | 200,533 | (1,435) |
Cash flows (used in)/from operating activities | (343,550) | 139,064 | (53,274) |
Interest paid | (349) | (124) | |
Income taxes paid | (2,450) | (4,356) | (565) |
NET CASH FLOWS (USED IN) / FROM OPERATING ACTIVITIES | (346,349) | 134,584 | (53,839) |
CASH FLOWS (USED IN) / FROM INVESTING ACTIVITIES | |||
Purchase of intangible assets | (3,503) | (40,143) | (62) |
Purchase of property, plant and equipment | (949) | (1,604) | (622) |
(Increase)/decrease in financial assets — current | 307,641 | (708,060) | (108,229) |
Interest received | 7,061 | 5,469 | 1,371 |
NET CASH FLOWS (USED IN) / FROM INVESTING ACTIVITIES | 310,250 | (744,338) | (107,542) |
CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES | |||
Principal elements of lease payments | (2,230) | (1,353) | |
Proceeds from issue of new shares, gross amount | 731,546 | 678,936 | 255,721 |
Issue costs paid | (551) | (22,999) | (14,655) |
Exchange gain from currency conversion on proceeds from issue of new shares | 62 | 1,354 | |
Proceeds from exercise of stock options | 19,070 | 4,775 | 2,251 |
NET CASH FLOWS (USED IN) / FROM FINANCING ACTIVITIES | 747,897 | 659,359 | 244,671 |
NET INCREASE (DECREASE) IN CASH & CASH EQUIVALENTS | 711,798 | 49,605 | 83,290 |
Cash and cash equivalents at the beginning of the period | 331,282 | 281,040 | 190,867 |
Exchange gains/(losses) on cash & cash equivalents | (51,471) | 637 | 6,883 |
Cash and cash equivalents at the end of the period | € 991,609 | € 331,282 | € 281,040 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - EUR (€) € in Thousands | Share capital | Share premium | Accumulated losses | Other reserves | Total equity attributable to owners of the parent | Total |
Equity at beginning of period at Dec. 31, 2017 | € 3,216 | € 430,518 | € (102,962) | € 11,764 | € 342,536 | € 342,536 |
Total comprehensive loss of the period | (66,641) | (66,641) | (66,641) | |||
Share-based payment | 19,183 | 19,183 | 19,183 | |||
Issue of share capital/ new shares | 347 | 255,374 | 255,721 | 255,721 | ||
Transaction costs for equity issue | (14,655) | (14,655) | (14,655) | |||
Exercise of stock options | 34 | 2,217 | 2,251 | 2,251 | ||
Equity at end of period at Dec. 31, 2018 | 3,597 | 673,454 | (169,603) | 30,947 | 538,395 | 538,395 |
Total comprehensive loss of the period | (162,965) | (162,965) | (162,965) | |||
Share-based payment | 39,552 | 39,552 | 39,552 | |||
Issue of share capital/ new shares | 637 | 678,299 | 678,936 | 678,936 | ||
Transaction costs for equity issue | (22,999) | (22,999) | (22,999) | |||
Accounting treatment of the share subscription agreement | (24,948) | (24,948) | (24,948) | |||
Exercise of stock options | 42 | 4,733 | 4,775 | 4,775 | ||
Equity at end of period at Dec. 31, 2019 | 4,276 | 1,308,539 | (332,568) | 70,499 | 1,050,746 | 1,050,746 |
Total comprehensive loss of the period | (528,923) | (528,923) | ||||
Total comprehensive income after reserves | (528,923) | (528,923) | ||||
Share-based payment | 84,479 | 84,479 | 84,479 | |||
Income tax benefit from excess tax deductions related to share-based payments | 8,006 | 8,006 | 8,006 | |||
Issue of share capital/ new shares | 421 | 731,125 | 731,546 | 731,546 | ||
Transaction costs for equity issue | (551) | (551) | (551) | |||
Exercise of stock options | 60 | 19,010 | 19,070 | 19,070 | ||
Equity at end of period at Dec. 31, 2020 | € 4,757 | € 2,058,123 | € (861,491) | € 162,984 | € 1,364,373 | € 1,364,373 |
General information about the c
General information about the company | 12 Months Ended |
Dec. 31, 2020 | |
General information about the company | |
General information about the company | 1. General information about the company argenx SE is a Dutch European public company with limited liability incorporated under the laws of the Netherlands. The company (COC 24435214) has its official seat in Rotterdam, the Netherlands, and its registered office is at Willemstraat 5, 4811 AH, Breda, the Netherlands. An overview of the company and its subsidiaries (the Company) are described in note 31. argenx SE is a publicly traded company with ordinary shares listed on Euronext Brussels under the symbol “ARGX” since July 2014 and with American Depositary Shares listed on Nasdaq under the symbol “ARGX” since May 2017. |
Impact of COVID-19 on our busin
Impact of COVID-19 on our business | 12 Months Ended |
Dec. 31, 2020 | |
Impacts of COVID-19 on our business | |
Impacts of COVID-19 on our business | 2. Impacts of COVID-19 on our business The current unprecedented challenges as a result of the COVID-19 outbreak have impacted how we operate. We have been taking, and continue to take, the necessary steps in terms of safety, risk mitigation, and financial measures to best manage through these challenging times. We have currently experienced limited impact on our financial performance and financial position, although we continue to face additional risks and challenges associated with the impact of the outbreak. |
Significant accounting policies
Significant accounting policies | 12 Months Ended |
Dec. 31, 2020 | |
Significant accounting policies | |
Significant accounting policies | 3. Significant accounting policies The significant Company’s accounting policies are summarized below. 3.1 Statement of compliance and basis of preparation The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB) and the interpretations issued by the IASB’s International Financial Reporting Interpretation Committee. The consolidated financial statements provide a general overview of the Company’s activities and the results achieved. They present fairly the entity’s financial position, its financial performance and cash flows, on a going concern basis. The significant accounting policies applied in the preparation of the above consolidated financial statements are set out below. All amounts are presented in thousands of euro, unless otherwise indicated, rounded to the nearest € ‘000. The consolidated financial statements have been approved for issue by the Company’s Board of Directors (the Board) on March 30, 2021. 3.2 Adoption of new and revised standards New New standards and interpretations for the annual period beginning on January 1, 2020 did not have any material impact on our consolidated financial statements. New standards and interpretations issued, but not yet applicable for the annual period beginning on January 1, 2020 We have not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective; The following new standards and amendments to standards have been issued, but are not mandatory for the first time for the financial year beginning January 1, 2020 and have been endorsed by the European Union. Amendments to IFRS 10 and IAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture The amendments to IFRS 10 and IAS 28 deal with situations where there is a sale or contribution of assets between an investor and its associate or joint venture. Specifically, the amendments state that gains or losses resulting from the loss of control of a subsidiary that does not contain a business in a transaction with an associate or a joint venture that is accounted for using the equity method, are recognised in the parent’s profit or loss only to the extent of the unrelated investors’ interests in that associate or joint venture. Similarly, gains and losses resulting from the remeasurement of investments retained in any former subsidiary (that has become an associate or a joint venture that is accounted for using the equity method) to fair value are recognised in the former parent’s profit or loss only to the extent of the unrelated investors’ interests in the new associate or joint venture. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IFRS 3 – Reference to the Conceptual Framework The amendments update IFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework . They also add to IFRS 3 a requirement that, for obligations within the scope of IAS 37, an acquirer applies IAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies , the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. Finally, the amendments add an explicit statement that an acquirer does not recognise contingent assets acquired in a business combination. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IAS 16 – Property, Plant and Equipment—Proceeds before Intended Use The amendments prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced before that asset is available for use, i.e. proceeds while bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Consequently, an entity recognises such sales proceeds and related costs in profit or loss. The entity measures the cost of those items in accordance with IAS 2 Inventories . The amendments also clarify the meaning of ‘testing whether an asset is functioning properly’. IAS 16 now specifies this as assessing whether the technical and physical performance of the asset is such that it is capable of being used in the production or supply of goods or services, for rental to others, or for administrative purposes. If not presented separately in the statement of comprehensive income, the financial statements shall disclose the amounts of proceeds and cost included in profit or loss that relate to items produced that are not an output of the entity’s ordinary activities, and which line item(s) in the statement of comprehensive income include(s) such proceeds and cost. The amendments are applied retrospectively, but only to items of property, plant and equipment that are brought to the location and condition necessary for them to be capable of operating in the manner intended by management on or after the beginning of the earliest period presented in the financial statements in which the entity first applies the amendments. The entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at the beginning of that earliest period presented. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IAS 37 – Onerous Contracts—Cost of Fulfilling a Contract The amendments specify that the ‘cost of fulfilling’ a contract comprises the ‘costs that relate directly to the contract’. Costs that relate directly to a contract consist of both the incremental costs of fulfilling that contract (examples would be direct labour or materials) and an allocation of other costs that relate directly to fulfilling contracts (an example would be the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract). The amendments apply to contracts for which the entity has not yet fulfilled all its obligations at the beginning of the annual reporting period in which the entity first applies the amendments. Comparatives are not restated. Instead, the entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings or other component of equity, as appropriate, at the date of initial application. These amendments are not expected to have any material impact on our consolidated financial statements. 3.3 Basis of consolidation The consolidated financial statements include the financial statements of the Company and entities controlled by the Company (its subsidiaries). Control is achieved when the Company; · has power over the investee; · is exposed, or has rights, to variable returns from its involvement with the investee; and · has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. The results of the subsidiaries are included in the consolidated statements of profit and loss and other comprehensive income from the effective date of acquisition up to the date when control ceases to exist. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by other members of the Group. All inter-company transactions and unrealized gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. 3.4 Foreign currency transactions 3.4.1 Functional and presentation currency Items included in the consolidated financial statements of each of our entities are valued using the currency of their economic environment in which the entity operates. The consolidated financial statements are presented in euro (€), which is the Company’s presentation currency. 3.4.2 Transactions and balances Transactions in foreign currencies are translated at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date. Foreign exchange differences arising on translation are recognized in the consolidated statements of profit and loss and other comprehensive income. Non‑monetary assets and liabilities denominated in foreign currencies are translated at the foreign exchange rate ruling at the date of the transaction. 3.4.3 Financial statements of foreign entities For foreign entities using a different functional currency than euro: · assets and liabilities for each consolidated statements of financial position presented are translated at the closing rate at the date of that statement of financial position. · income and expenses for each statement presenting profit or loss and other comprehensive income are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions). · all resulting exchange differences are recognised in other comprehensive income. 3.5 Intangible assets 3.5.1 Internally generated intangible assets Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally‑generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: · the technical feasibility of completing the intangible asset so that it will be available for use or sale; · the intention to complete the intangible asset and use or sell it; · the ability to use or sell the intangible asset; · how the intangible asset will generate probable future economic benefits; · the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and · the ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally‑generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally‑generated intangible asset can be recognized, development expenditures are recognized in the consolidated statements of profit and loss and other comprehensive income in the period in which they are incurred. Due to uncertainties inherent to the development and registration with the relevant healthcare authorities of its products, the Company estimates that the conditions for capitalization are not met until the regulatory procedures required by such healthcare authorities have been finalized. The Company currently does not own products that have been approved by the relevant healthcare authorities and this has resulted in all development costs being recognized as an expense in the period in which they are incurred. 3.5.2 Acquired In-Process R&D, Software and Databases and Other intangible assets Intangible assets with finite useful lives that are acquired separately related to in-process research and development projects, software and databases and other intangible assets are carried at cost less accumulated amortization and accumulated impairment losses. Intangible assets with indefinite useful lives are carried at cost less accumulated impairment losses. Payments for acquired in-process research and development projects obtained through in-licensing arrangements are capitalized as intangible assets provided that they are separately identifiable, controlled by the Company and expected to provide future economic benefits. As the probability criterion in IAS 38 is always considered to be satisfied for separately acquired research and development assets and the amount of the payments is determinable, upfront and milestone payments to third parties for pharmaceutical products or compounds for which regulatory marketing approval has not yet been obtained are recognized as intangible assets. Other intangible assets includes the Priority Review Voucher (“PRV”) acquired in 2020 which the Company can use to obtain the priority review by the FDA for one of its future regulatory submissions or may sell or transfer to a third party. The PRV is measured at cost and reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable. At the time the Company commits using the PRV to accelerate the review of a drug application, the intangible asset will be amortized and derecognized upon filing of the related Biologic License Application. 3.5.3 Amortization of intangible assets Intangible assets, which comprises of acquired in-process research and development, software and databases and other intangible assets, are amortized on a straight-line basis over the estimated useful life as from the time they are available for use, or when the underlying drug candidate is approved, generally on the following basis: · Acquired In-Process R&D – the longer of the patent protection life and the useful life of the combined product · Software and Databases – 3 – 5 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. 3.5.4 Derecognition of intangible assets An intangible asset is derecognized either on disposal or when no future economic benefits are expected from its use. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds, if any, and the carrying amount of the asset, are recognized in the consolidated statements of profit and loss and other comprehensive income when the asset is derecognized. 3.6 Property, plant and equipment Items of property, plant and equipment held for use in the production or supply of goods or services, or for administrative purposes, are stated in the statement of financial position at their cost, less accumulated depreciation and impairment losses. Depreciation is recognized as from acquisition date onwards (unless asset is not ready for use) so as to write off the cost or valuation of assets (other than freehold land and properties under construction) less their residual values over their useful lives, using the straight‑line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. Unless revised due to specific changes in the estimated useful life, annual depreciation rates are as follows: · Office and lab equipment: 3–5 years · IT equipment: 3 years An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds, if any, and the carrying amount of the asset and is recognized in the consolidated statements of profit or loss and other comprehensive income. 1.7 Inventories Inventories are carried at cost or net realisable value, whichever is lowest. Cost is determined using the first-in, first-out method. Cost comprises of costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. If the expected sales price less completion costs to execute sales (net realizable value) is lower than the carrying amount, a write-down is recognised for the amount by which the carrying amount exceeds its net realisable value. Included in inventory are products which could, besides commercial activities, be used in preclinical and clinical programs as well as in non-reimbursed Early Access Programs. These products are charged to research & development expenses or selling, general and administrative expenses, respectively, when dedicated to this channel. We capitalize inventory costs associated with products prior to the regulatory approval of these products, or for inventory produced in new production facilities, when it is highly probable that the pre-approval inventories will be saleable. The determination to capitalize is based on the particular facts and circumstances relating to the expected regulatory approval of the product or production facility being considered. The assessment of whether or not the product is considered highly probable to be saleable is made on a quarterly basis and includes, but is not limited to, how far a particular product or facility has progressed along the approval process, any known safety or efficacy concern, potential labelling restrictions and other impediments. Previously capitalized costs related to pre-launch inventories could be required to be written down upon a change in such judgement or due to a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors, which will be recorded to research and development expenses. 1.8 Leases As of January 1, 2019, the Company has changed its accounting policy for leases where the Company is the lessee. 3.8.1 Accounting policy until December 31, 2018 Leases of property, plant and equipment where the Company, as lessee, had substantially all the risks and rewards of ownership were classified as finance leases. Finance leases were capitalised at the lease’s inception at the fair value of the leased property or, if lower, the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, were included in other short-term and long-term payables. Each lease payment was allocated between the liability and finance cost. The finance cost was charged to the profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The property, plant and equipment acquired under finance leases was depreciated over the asset’s useful life or over the shorter of the asset’s useful life and the lease term if there is no reasonable certainty that the Company will obtain ownership at the end of the lease term. Leases in which a significant portion of the risks and rewards of ownership were not transferred to the Company as lessee were classified as operating leases. Operating lease payments were recognized as an expense on a straight‑line basis over the lease term, except where another systematic basis was more representative of the time pattern in which economic benefits from the leased asset are consumed. The Company has adopated IFRS 16 on January 1, 2019. The Company elected to apply the modified retrospective approach for the transition, which foresees that prior period figures remain as reported under the previous standard IAS 17, and the cumulative effect of applying IFRS 16 is recognized as an adjustment to the opening balance of equity as of the date of initial application (i.e., the beginning of the year 2019). On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under IAS 17. These liabilities were measured at the present value of the remaining lease payments and discounted using the Company’s incremental borrowing rate as of January 1, 2019. The Company’s weighted average incremental borrowing rate applied to these lease liabilities on January 1, 2019 was 1.32%. The differences between our total operating lease commitments as reported in note 5.7 of our consolidated financial statements of December 31, 2018 and the total lease liabilities recognized in our statement of financial position as at January 1, 2019 are summarized below: (in thousands of €) Operating lease commitments disclosed as at December 31, 2018 € 3,004 Less: discounting effect using the lessee's incremental borrowing rate of the date of initial application € (126) Less: short-term leases recognized on a straight-line basis as expense € (88) Lease liability recognized as at January 1, 2019 € 2,790 of which are: Current lease liabilities € 1,078 Non-current lease liabilities € 1,712 The cumulative effect of adopting IFRS 16 to the consolidated statements of financial position as of January 1, 2019 is as follows: (in thousands of €) Property, plant and equipment (right-of-use assets) € 2,790 Effect on total assets € 2,790 Lease liabilities (current and non-current) € 2,790 Effect on total equity and liabilities € 2,790 The Company has elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4 Determining whether an Arrangement contains a Lease . 3.8.2 Accounting policy as from January 1, 2019 As from January 1, 2019, the Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee uses its incremental borrowing rate. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The lease liability is presented as a separate line in the consolidated statements of financial position. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The right-of-use assets are presented in the consolidated statements of financial position under the caption “Property, plant and equipment”. 3.9 Impairment of assets 3.9.1 Financial Assets The impairment loss of a financial asset measured at amortised cost is calculated based on the expected loss model. For trade receivables, in the absence of a significant financing component, the allowance is measured at an amount equal to lifetime expected credit losses. Those are the expected credit losses that result from possible default events over the expected life of those trade receivables. 3.9.2 Property, plant and equipment and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash‑generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. If the recoverable amount of an asset or cash‑generating unit is estimated to be less than its carrying amount, the carrying amount of the asset or cash‑generating unit is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of profit or loss and other comprehensive income. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset or cash‑generating unit in prior years. A reversal of an impairment loss is recognized immediately in profit or loss. 3.10 Financial instruments Financial assets and financial liabilities are recognized in the consolidated statements of financial position when the Company becomes party to the contractual provisions of the instrument. The Company does not use currency derivatives to hedge planned future cash flows, nor does it make use of forward foreign exchange contracts. Additionally, the Company does not have financial debt at December 31, 2020. 3.10.1 Financial assets Financial assets are initially recognized either at fair value or at transaction price. All recognized financial assets are subsequently measured at either amortized cost or fair value under IFRS 9 on the basis of both the Company’s model for managing the financial assets and the contractual cash flow characteristics of the financial asset. · A financial asset that (i) is held within a business model whose objective is to collect the contractual cash flows and (ii) has contractual cash flows that are solely payments of principal and interest on the principal amount outstanding is measured at amortized cost (net of any write down for impairment), unless the asset is designated at fair value through profit or loss (FVTPL) under the fair value option. · A financial asset that (i) is held within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets and (ii) has contractual term that give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding, is measured at fair value through other comprehensive income (FVTOCI), unless the asset is designated at FVTPL under the fair value option. · All other financial assets are measured at FVTPL. A financial asset is classified as current when the cash flows expected to flow from the instrument mature within one year. The Company derecognized a financial asset when the contractual rights to the cash flows from the asset expire, or the Company transfers the right to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. The Company classifies non-derivative financial assets into the following categories; · financial asset at fair value through profit or loss (non-current financial assets, current financial assets and cash equivalents) · financial assets at amortized cost (receivables and cash and cash equivalents) Financial assets at fair value through profit or loss Financial assets are designated at fair value through profit or loss if the Company manages such investments and makes purchases and sales decisions based on their fair value in accordance with the Company’s investment strategy. Attributable transaction costs are recognised in the consolidated statements of profit or loss and other comprehensive income as incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein, which take into account any dividend income, are recognized in the consolidated statements of profit or loss and other comprehensive income. 3.10.1.1 Non-current financial assets The Company holds investments in non-current financial assets, which based on IFRS 9, are designated as financial assets at fair value through profit or loss, which qualify for level 3 fair value measurement based on current market prices. If the market for a financial asset is not active (and for unlisted securities), the Company established fair value by using valuation techniques. 3.10.1.2 Current financial assets Current financial assets include financial assets measured at fair value through profit or loss and comprise of money market funds and term accounts that have an initial maturity equal or less than 12 months, but exceeding 3 months. 3.10.1.3 Cash equivalents measured at fair value through profit or loss Cash equivalents measured at fair value through profit or loss may comprise of term accounts that have an initial maturity of equal or less than 3 months and money market funds that are readily convertible to cash and are subject to insignificant risk of changes in value. These financial assets are used by the Company in the management of the short-term commitments. Financial assets at amortized cost 3.10.1.4. Receivables Trade and other receivables are designated as financial assets measured at amortized cost. They are initially measured either at fair value or at transaction price, in the absence of a significant financing component. All receivables are subsequently measured at amortized cost, which generally corresponds to nominal value less expected credit loss provision. Receivables mainly comprise trade and other receivables and current and non-current research and development incentive receivables. These research and development incentive receivables relate to refunds resulting from research and development incentives on research and development expenses in Belgium and are credited to the consolidated statements of profit or loss and other comprehensive income under the line “Other operating income” when the relevant expenditure has been incurred and there is a reasonable assurance that the research and development incentives are receivable. 3.10.1.5 Cash Cash are financial assets measured at amortized cost and comprise of cash balances and savings accounts. 3.10.1.6 Cash equivalents measured at amortized costs Cash equivalents measured at amortized cost comprise of term accounts that have an initial maturity of less than 3 months that are subject to an insignificant risk of changes in values. The financial assets are used by the Company in the management of short-term commitments. Cash and cash equivalents exclude restricted cash, which is presented in the consolidated statements of financial position under the line “Restricted cash – current” and “Other non-current assets”. 3.10.2 Financial Liabilities Financial liabilities are initially measured at their transaction price. Subsequent to initial recognition, financial liabilities are measured at amortized cost. Financial liabilities mainly comprise of trade and other liabilities. Trade and other liabilities are comprised of liabilities that are due less than one year from the balance sheet date and are in general not interest bearing and settled on an ongoing basis during the financial year. They also include accrued expense related to the Company’s research and development costs. 3.11 Shareholder’s equity An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs. The Company has never distributed any dividends to its shareholders. As of December 31, 2020, no profits were available for distribution. 3.12 Provisions Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probabl |
Critical accounting judgements
Critical accounting judgements and key sources of estimation uncertainty | 12 Months Ended |
Dec. 31, 2020 | |
Critical accounting judgements and key sources of estimation uncertainty | |
Critical accounting judgements and key sources of estimation uncertainty | 4. Critical accounting judgements and key sources of estimation uncertainty In the application of the Company’s accounting policies, which are described above, the Company is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. The following areas are areas where key assumptions concerning the future, and other key sources of estimation uncertainty at the end of the reporting period, have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year. Critical estimates in applying accounting policies Research and development cost accruals The Company recognizes costs of €52.6 million, as specified in note 15 to the financial statements, incurred for clinical trial activities and manufacturing of drug products, as research and development expenses based on an evaluation of its vendors’ progress toward completion of specific tasks. Timing of payment may differ significantly from the period in which the costs are recognized as expense, resulting in clinical trial accruals recognized within “Trade and other payables” in the consolidated statements of financial position. Quantification of the research progress and the translation of the progress to these accruals requires estimates, because the progress is not directly observable. In estimating the vendors’ progress toward completion of specific tasks, the Company therefore uses non-financial data such as patient enrollment, clinical site activations and vendor information of actual costs incurred. This data is obtained through reports from or discussions with Company personnel and outside service providers as to the progress or state of completion of trials, or the completion of services. Costs are expensed over the service period the services are provided. Costs for services provided that have not yet been paid are recognized as accrued expenses. Research and development cost accruals directly impact the revenue recognized, given the satisfaction of the single performance obligation is measured using the input method. |
Intangible assets
Intangible assets | 12 Months Ended |
Dec. 31, 2020 | |
Intangible assets | |
Intangible assets | 5. (in thousands of €) Acquired In-Process R&D Software & databases Other Intangibles Total Cost On January 1, 2018 € — € 99 € — € 99 Additions — 62 — 62 Disposals — (2) — (2) On December 31, 2018 — 159 — 159 Additions 39,881 262 — 40,143 On December 31, 2019 39,881 421 — 40,302 Additions 13,236 2,503 80,725 96,464 On December 31, 2020 € 53,117 € 2,924 € 80,725 € 136,766 Amortization and impairment On January 1, 2018 € — € (86) € — € (86) Amortization — (19) — (19) Disposals — 2 — 2 On December 31, 2018 — (103) — (103) Amortization — (38) — (38) On December 31, 2019 — (141) — (141) Amortization — (215) — (215) On December 31, 2020 € — € (356) € — € (356) Carrying Amount On December 31, 2018 € — € 56 € — € 56 On December 31, 2019 39,881 280 — 40,161 On December 31, 2020 € 53,117 € 2,568 € 80,725 € 136,410 The Company performed an annual impairment review on the intangible assets not yet available for use. This review did not result in the recognition of an impairment charge. As of December 31, 2020, there are no commitments to acquire additional intangible assets, except as set forth in note 29. No intangible assets are pledged as security for liabilities nor are there any intangible assets whose title is restricted. |
Property, plant and equipment
Property, plant and equipment | 12 Months Ended |
Dec. 31, 2020 | |
Property, plant and equipment. | |
Property, plant and equipment | 6. IT, office and lab Right-of-use assets Right-of-use assets Leasehold Lease (in thousands of €) equipment Buildings Vehicles improvements equipment (1) Total Cost On January 1, 2018 € 2,389 € — € — € — € — € 2,389 Additions 370 — — — 253 623 Disposals (47) — — — — (46) On December 31, 2018 2,712 — — — 253 2,965 Adoption of IFRS 16 — 2,338 452 — — 2,790 Additions 765 4,553 525 808 29 6,680 On December 31, 2019 3,477 6,891 977 808 282 12,435 Additions 597 2,718 875 352 — 4,542 Disposals (90) — — — — (90) On December 31, 2020 € 3,984 € 9,609 € 1,852 € 1,160 € 282 € 16,887 Depreciation and impairment On January 1, 2018 € (1,713) € — € — € — € — € (1,713) Depreciation (463) — — — (11) (474) Disposals 46 — — — — 46 On December 31, 2018 (2,130) — — — (11) (2,141) Depreciation (460) (1,315) (233) (92) (28) (2,128) On December 31, 2019 (2,590) (1,315) (233) (92) (39) (4,269) Depreciation (468) (1,981) (386) (351) (28) (3,214) Disposals 90 — — — — 90 On December 31, 2020 € (2,968) € (3,296) € (619) € (443) € (67) € (7,393) Carrying Amount On December 31, 2018 € 582 € — € — € — € 242 € 824 On December 31, 2019 887 5,576 744 716 243 8,167 On December 31, 2020 € 1,016 € 6,313 € 1,233 € 717 € 215 € 9,494 (1) The Company has elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4 Determining whether an Arrangement contains a Lease. There are no commitments to acquire property, plant and equipment. Furthermore, no items of property, plant and equipment are pledged. See note 22 for information for leases where the Company is a lessee. |
Other non-current assets
Other non-current assets | 12 Months Ended |
Dec. 31, 2020 | |
Miscellaneous non-current assets [abstract] | |
Other non-current assets | 7. Other non-current assets consisted of non-current restricted cash and financial assets held at fair value through profit or loss. Year Ended December 31, (in thousands of €) 2020 2019 2018 Restricted Cash - non-current € 1,243 € 630 € 251 Non-current financial assets held at fair value through profit or loss 5,140 2,596 1 Total other non-current assets € 6,383 € 3,226 € 252 Non-current restricted cash on December 31, 2020 was mainly composed of deposit guarantees paid under the lease agreements for the laboratory and offices of the Company. Non-current financial assets held at fair value through profit or loss is comprised of the profit share in AgomAb Therapeutics NV. In March 2019, the Company entered into a license agreement with AgomAb Therapeutics NV for the use of HGF-mimetic SIMPLE Antibodies™, developed under the Company’s Innovative Access Program. In exchange for granting this license, the Company received a profit share in AgomAb Therapeutics NV. In March 2019, AgomAb Therapeutics NV secured €21.0 million in a Series A financing round. The Company used the post-money valuation of this Series A financing round and the number of outstanding shares in determining the fair value of the profit sharing instrument and the revaluation of this instrument. This instrument is designated as financial asset held at fair value through profit or loss which qualify for level 3 fair value measurement currently based upon the Series A financing round valuation. Fair value changes on non-current financial assets with fair value through profit of loss are recognized in the consolidated statements of profit and loss and other comprehensive income in line “ Change in fair value on non-current financials assets”. The table below illustrates these non-current financials assets at fair value through profit or loss as of December 31, 2020, 2019 and 2018. Year Ended December 31, (in thousands of €) 2020 2019 2018 Cost at January 1 € 1,499 € — € — Acquisitions of the year — 1,499 — Cost at December 31 € 1,499 € 1,499 € — Fair value adjustments at January 1 € 1,097 € — € — Fair value adjustment of the year 2,544 1,097 — Fair value adjustment at December 31 € 3,641 € 1,097 € — Net book value at December 31 € 5,140 € 2,596 € — 3. |
Deferred Taxes
Deferred Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Deferred Taxes | |
Deferred Taxes | 8. The amount of deferred tax assets and liability by type of temporary difference can be detailed as follows: Year Ended December 31, 2020 (in thousands of €) Assets Liabilities Net Deferred tax assets / (liabilities) Accruals and allowances € 1,750 € — € 1,750 Income tax benefit from excess tax deductions related to share-based payments 10,889 — 10,889 Property, plant and equipment — (136) (136) Intangible assets — (1,460) (1,460) Netting by taxable entity (384) 384 — Net deferred tax assets / (liabilities) € 12,255 € (1,212) € 11,043 The change in net deferred taxes recorded in the consolidated statement of financial position can be detailed as follows: (in thousands of €) Deferred tax assets Deferred tax liabilities Balance at January 1, 2020 € — € — Recognized in profit or loss 7,311 (1,212) Recognized in equity 5,073 — Effects of change in foreign exchange rate (129) — Balance at December 31, 2020 € 12,255 € (1,212) 8. |
Inventories
Inventories | 12 Months Ended |
Dec. 31, 2020 | |
Inventories | |
Inventories | 9. Year Ended December 31, (in thousands of €) 2020 2019 2018 Raw materials and consumables € 15,164 € — € — Inventories in process 5,368 — — Finished goods — — — Total inventories € 20,532 € — € — On December 31, 2020, inventories amounted to €20.5 million and related to pre-launch efgartigimod-inventory, capitalized subsequent to the announcement of the topline data from the pivotal ADAPT trial of efgartigimod. As of December 31, 2020, no inventory write-downs were recorded. |
Trade and other receivables
Trade and other receivables | 12 Months Ended |
Dec. 31, 2020 | |
Trade and other receivables | |
Trade and other receivables | 10. The trade and other receivables are composed of receivables which are detailed below: Year Ended December 31, (in thousands of €) 2020 2019 2018 Trade receivable € 234 € 22,580 € 214 Interest receivable 809 2,081 556 Other receivable 4,644 3,454 2,116 € 5,687 € 28,115 € 2,886 The carrying amounts of trade and other receivables approximate their respective fair values. Other receivables mainly included accrued income from subsidy projects and VAT receivables. Please also refer to note 26 for more information on the financial instruments. |
Financial assets - current
Financial assets - current | 12 Months Ended |
Dec. 31, 2020 | |
Financial assets - current | |
Financial assets - current | 11. Financial assets — current These current financial assets relate to term accounts with an initial maturity longer than 3 months but less than 12 months and money market funds that do not qualify as cash equivalents. Year Ended December 31, (in thousands of €) 2020 2019 2018 Money market funds € 106,177 € 715,773 € 283,529 Term accounts 529,182 288,766 — € 635,359 € 1,004,539 € 283,529 On December 31, 2020, the current financial assets included $717.1 million held in USD, which could generate a foreign currency exchange gain or loss in our financial results in accordance with the fluctuations of the EUR/USD exchange rate as the Company’s functional currency is EUR. Please also refer to note 26 for more information on the financial instruments. |
Cash and cash equivalents
Cash and cash equivalents | 12 Months Ended |
Dec. 31, 2020 | |
Cash and cash equivalents | |
Cash and cash equivalents | 12. Cash and cash equivalents Year Ended December 31, (in thousands of €) 2020 2019 2018 Money market funds € 699,447 € — € — Term accounts 50,001 227,551 217,451 Cash and bank balances 242,161 103,731 63,589 € 991,609 € 331,282 € 281,040 Cash and cash equivalents may comprise of cash and bank balances, saving accounts, term accounts with an original maturity not exceeding 3 months and money market funds that are readily convertible to cash and are subject to an insignificant risk of changes in value. Cash positions are invested with preferred financial partners, which are mostly considered to be high quality financial institutions with sound credit ratings to reduce credit risk. On December 31, 2020, the cash and cash equivalents included $576.1 million held in USD, which could generate a foreign currency exchange gain or loss in our financial results in accordance with the fluctuations of the EUR/USD exchange rate as the Company’s functional currency is EUR. Please also refer to note 26 for more information on the financial instruments. |
Share capital and share premium
Share capital and share premium | 12 Months Ended |
Dec. 31, 2020 | |
Share capital and share premium | |
Share capital and share premium | 13. Share capital and share premium On December 31, 2020, the Company’s share capital was represented by 47,571,283 shares. All shares were issued, fully paid up and of the same class. The table below summarizes our capital increases, as a result of offerings and the exercise of stock options under the Company’s Employee Stock Option Plan. Roll forward of number of shares outstanding: Number of shares outstanding on January 1, 2018 32,180,641 Exercise of stock options 319,671 U.S. third public offering on Nasdaq on September 18, 2018 3,475,000 Number of shares outstanding on December 31, 2018 35,975,312 Exercise of stock options 419,317 Share subscription from Johnson & Johnson Innovation Inc. 1,766,899 Global public offering on Euronext and Nasdaq on November 7, 2019 4,000,000 Over-allotment option exercised by underwriters on November 8, 2019 600,000 Number of shares outstanding on December 31, 2019 42,761,528 Exercise of stock options 602,463 Global public offering in Euronext and Nasdaq on May 28, 2020 3,658,515 Over-allotment option exercised by underwriters on May 29, 2020 548,777 Number of shares outstanding on December 31, 2020 47,571,283 On May 12, 2020 at the annual general meeting, the shareholders of the Company approved the authorization to the Board to issue: · A maximum of 10% of the then-outstanding share capital for a period of 18 months · A maximum of 10% of the then-outstanding share capital for a period till December 31, 2020 On December 31, 2020, an amount of €427,974.7, represented by 4,279,747 shares, still remained available under the authorized capital . |
Share based payments
Share based payments | 12 Months Ended |
Dec. 31, 2020 | |
Share based payments | |
Share based payments | 14. Share-based payments The Company has a stock options scheme for the employees of the Company and its subsidiaries. In accordance with the terms of the plan, as approved by shareholders, employees may be granted stock options to purchase ordinary shares at an exercise price as mentioned below per ordinary share. The stock options are granted to employees, consultants or directors of the Company and its subsidiaries. The stock options have been granted free of charge. Each employee’s stock option converts into one ordinary share of the Company upon exercise. The stock options carry neither rights to dividends nor voting rights. Stock options may be exercised at any time from the date of vesting to the date of their expiry. The regular stock options granted vest, in principle, as follows: · 1/3rd of the regular stock options granted will vest on the first anniversary of the granting of the stock options, and · 1/24th of the remaining 2/3rd of regular stock options granted will vest on the last day of each of the 24 months following the month of the first anniversary of the granting of the stock options. The sign-on stock options granted vest, in principle, as follows: · 1/4rd of the stock options granted will vest on the first anniversary of the granting of the stock options, and · 1/36th of the remaining 3/4th of the stock options granted will vest on the last day of each of the 36 months following the month of the first anniversary of the granting of the stock options. In order to prefinance the taxes that are paid upon the grant of stock options, Belgian employees have the ability, in exchange for the taxes due upon the grant of the stock options, to transfer the economic benefits related to part of those stock options to a third party. As of December 31, 2020, the economic benefits of 126,982 stock options, for which accelerated vesting applies, were transferred to a third party. No other conditions are attached to the stock options. The following share-based payment arrangements were in existence during the current and prior years and which are exercisable at the end of each period presented: Exercise price Outstanding per stock stock options on options December 31, Expiry date (in €) 2020 2019 2018 2020 € 3.95 — 7,210 18,200 2023 2.44 165,693 211,769 294,400 2024 2.44 100,086 102,696 144,703 2024 3.95 6,238 6,238 6,895 2024 7.17 294,167 335,067 407,061 2025 11.44 21,500 39,000 39,000 2025 10.34 950 3,000 3,000 2025 9.47 114,232 185,832 226,323 2026 11.38 45,000 45,000 50,415 2026 11.47 127,252 219,791 257,616 2026 14.13 176,426 258,746 315,102 2027 18.41 102,479 108,613 114,019 2027 21.17 460,701 565,798 628,292 2023 80.82 85,077 94,100 94,600 2028 80.82 49,532 73,100 75,450 2023 86.32 325,661 366,260 369,760 2028 86.32 381,317 402,714 491,815 2024 113.49 111,174 111,690 — 2029 113.49 163,410 299,560 — 2024 135.75 195,452 204,430 — 2029 135.75 692,914 717,455 — 2025 119.53 19,000 — — 2030 119.53 123,700 — — 2025 196.15 131,770 — — 2030 196.15 325,150 — — 2025 200.22 32,100 — — 2030 200.22 175,200 — — 2030 247.60 31,200 — — 2025/2030 (1) € 247.60 908,362 — — 5,365,743 4,358,069 3,536,651 (1) In December 2020, the Company granted options for which the beneficiaries had a 60-day period to choose between a contractual term of five or ten years. 2020 2019 2018 Number of Weighted average Number of Weighted average Number of Weighted average stock options exercise price stock options exercise price stock options exercise price Outstanding at January 1 4,358,069 € 63.75 3,536,651 € 33.42 2,862,216 € 11.54 Granted 1,797,652 217.35 1,365,172 128.52 1,040,475 85.37 Exercised (602,463) 31.67 (419,317) 11.35 (319,671) 7.02 Forfeited (187,515) 139.34 (124,437) 88.92 (46,369) 30.44 Outstanding at December 31 5,365,743 116.43 4,358,069 63.75 3,536,651 33.42 Exercisable at December 31 2,833,680 € 53.17 2,203,476 € 22.59 1,859,315 € 9.62 The weighted average share price at the date of exercise of options exercised during the year ended December 31, 2020 was €207.43, compared to €110.99 during the year ended December 31, 2019 and €66.93 during the year ended December 31, 2018. The weighted average remaining contractual life of the stock options outstanding amounted to 7.08 years on December 31, 2020 compared to 7.27 years on December 31, 2019 and 7.82 years on December 31, 2018. The table below shows the weighted average remaining contractual life for each range of exercise price: Weighted average remaining Outstanding on contractual life Exercise price (in €) December 31, 2020 (in years) 2.44 - 3.95 272,017 3.08 7.17 - 9.47 408,399 4.24 10.34 - 14.13 371,128 5.62 18.41 - 21.17 563,180 6.87 80.82 - 86.32 841,587 5.46 113.49 - 135.75 1,305,650 7.64 196.15 - 247.60 1,603,782 9.29 The fair market value of the stock options has been determined based on the Black and Scholes model using the following unobservable assumptions: · The expected volatility, determined on the basis of the implied volatility of the share price over the expected life of the option. · The expected option life, calculated as the estimated duration until exercise, taking into account the specific features of the plans. Below is an overview of the parameters used in relation to the determination of the fair value of the grants during 2020: Stock options granted in April 2020 June 2020 Oct 2020 Dec 2020 Number of options granted 142,700 550,090 196,500 908,362 Fair value of options (in EUR) € 62.31 - 120.63 € 68.01 - 105.65 € 74.24 - 127.68 € 119.26 - 124.67 Share price (in EUR) € 126.50 - 205.60 € 183.20 - 229.20 € 209.00 - 239.20 € 247.4 Exercise price (in EUR) € 119.53 € 196.15 € 200.22 € 247.6 Expected volatility 44.44 - 64.77 % 43.46 - 52.19 % 44.17 - 52.71 % 53.00 - 53.51 % Expected option life (in years) 4 - 6.68 4 - 6.68 4 - 6.68 6.15 - 6.68 (1) Risk‑free interest rate (0.32) - (0.18) % (0.43) - (0.28) % (0.51) - (0.34) % (0.42) - (0.40) % Expected dividends — % — % — % — % (1) In December 2020, the Company granted a total of 908,362 stock options. The beneficiary can choose between a contractual term of five or ten years. The expected option life ranges between 6.15 and 6.68 years. This estimate will be reassessed once the acceptance period of 60 days has passed and the beneficiaries will have made a choice between a contractual term of five or ten years. The total fair value of the grant would range from €84.5 million (100% of the stock options with a contractual term of five years) to €110.3 million (100% of the stock options with a conctractual term of ten years ). Below is an overview of the parameters used in relation to the determination of the fair value of grants during 2019: Stock options granted in June 2019 Nov 2019 Dec 2019 Number of options granted 423,487 19,800 921,885 Average Fair value of options (in EUR) € 63.45 € 57.69 € 41.40 - 66.39 Share price (in EUR) € 123.20 € 126.40 € 130.1 - 150.7 Exercise price (in EUR) € 113.49 € 113.49 € 135.75 Expected volatility 45.25 % 44.14 43.80 - 44.11 % Average Expected option life (in years) 8.59 6.50 4 - 6.5 Risk‑free interest rate 0.07 % (0.05) (0.57) - (0.24) % Expected dividends — % — — % Below is an overview of the parameter used in relation to the determination of the fair value of grants during 2018: Stock options granted in June 2018 Dec 2018 Number of options granted 178,900 861,575 Fair value of options (in EUR) € 32.12 € 39.85 Share price (in EUR) € 72.00 € 82.20 Exercise price (in EUR) € 80.82 € 86.32 Expected volatility 45.50 % 46.19 % Average expected option life (in years) 7.36 7.83 Risk‑free interest rate 0.72 % 0.77 % Expected dividends — % — % The total share-based payment expense recognized in the consolidated statement of comprehensive income totaled €84.5 million for the year ended December 31, 2020, compared to €39.6 for the year ended December 31, 2019 and €19.2 million for the year ended December 31, 2018. |
Trade and other payables
Trade and other payables | 12 Months Ended |
Dec. 31, 2020 | |
Trade and other payables | |
Trade and other payables | 15. Trade and other payables Year Ended December 31, (in thousands of €) 2020 2019 2018 Trade payables € 168,140 € 58,429 € 24,152 Short‑term employee benefits 56,122 26,872 12,920 € 224,262 € 85,301 € 37,072 Trade payables correspond primarily to clinical and manufacturing activities and include accrued expenses related to these activities. As of December 31, 2020, the trade payables include accruals amounting to €52.6 million related to accruals from clinical manufacturing organizations for the manufacturing of drug products and from clinical research organisations. Short‑term employee benefits include payables and accruals for salaries and bonuses to be paid to the employees of the Company. |
Revenue
Revenue | 12 Months Ended |
Dec. 31, 2020 | |
Revenue | |
Revenue | 16. Revenue The following table summarizes details of revenues for the year ended December 31, 2020, 2019 and 2018 by collaboration agreement and by category of revenue: upfront payments, milestone payments and research and development service fees. Year Ended December 31, (in thousands of €) 2020 2019 2018 Upfront payments € 30,348 € 22,360 € 8,635 Janssen 29,818 20,056 — AbbVie 497 761 8,455 Agomab — 1,499 — Other 33 44 180 Milestone payments 3,021 28,085 11,440 Janssen 2,333 1,569 — AbbVie 671 26,494 10,510 Other 17 22 930 Research and development service fees 3,056 19,338 1,407 Janssen 2,807 18,968 — Other 249 370 1,407 Total revenue € 36,425 € 69,783 € 21,482 For the years ended December 31, 2020, 2019 and 2018, the majority of the revenue was generated under the agreements with Janssen and AbbVie, each as described below. The table below summarizes the changes in deferred revenue – current and deferred revenue -non-current for the year ended December 31, 2020, 2019 and 2018. (in thousands of €) Janssen AbbVie Other Total On January 1, 2018 € — € 12,376 € 344 € 12,720 Received Milestone — 8,633 883 9,516 Revenue recognition Upfront — (8,455) (180) (8,635) Milestone — (10,510) (930) (11,440) On December 31, 2018 — 2,045 116 2,161 Received Upfront 288,060 288,060 Milestone 22,535 26,560 49,095 Revenue recognition Upfront (20,056) (761) (44) (20,861) Milestone (1,569) (26,494) (22) (28,085) On December 31, 2019 288,971 1,350 50 290,371 Received Milestone — — — — Revenue recognition Upfront (29,818) (497) (33) (30,348) Milestone (2,333) (671) (17) (3,021) On December 31, 2020 € 256,819 € 182 € (0) € 257,001 Below are summaries of the key collaborations. AbbVie In April 2016, the Company entered into a collaboration agreement with AbbVie S.À.R.L. (AbbVie) to develop and commercialize ARGX-115 (ABBV-151). Under the terms of the collaboration agreement, the Company was responsible for conducting and funding all ARGX‑115 (ABBV-151) research and development activities up to completion of IND enabling studies. The Company granted AbbVie an exclusive option, for a specified period following completion of IND enabling studies, to obtain a worldwide, exclusive license to the ARGX‑115 (ABBV-151) program to develop and commercialize products. The Company received an upfront, nonrefundable, non-creditable payment of $40 million (€35.1 million as of the date the payment was received) from AbbVie for the exclusive option to license ARGX‑115 (ABBV-151). The Company achieved two preclinical milestones, each of which triggered a $10.0 million payment (€8.9 million based on the exchange rate in effect as of the date the first milestone payment was received, and €8.7 million based on the exchange rate in effect as of the date the second milestone payment was received). In August 2018, AbbVie exercised its option and has assumed certain development obligations, being solely responsible for all research, development and regulatory costs relating to ARGX-115 based products. In March 2019, the Company achieved the first development milestone upon initiation of a first-in-human clinical trial, triggering a $30.0 million payment. Subject to the continuing progress of ARGX-115 (ABBV-151) by AbbVie, the Company is eligible to receive development, regulatory and commercial milestone payments in aggregate amounts of up to $110 million, $190 million and $325 million, respectively, as well as tiered royalties on sales at percentages ranging from the mid‑single digits to the lower teens, subject to customary reductions. The Company has the right, on a product‑by‑product basis to co‑promote ARGX‑115 (ABBV-151) based products in the European Economic Area and Switzerland and to combine the product with the Company’s own future immuno‑oncology programs. The co‑promotion effort would be governed by a co‑promotion agreement negotiated in good faith by the parties. AbbVie will fund further GARP‑related research by the Company for an initial period of two years. AbbVie will have the right to license additional therapeutic programs emerging from this research, for which the Company could receive associated milestone and royalty payments. With regard to its collaboration with AbbVie, the Company concluded as follows: · There is one single performance obligation under IFRS 15, that being the transfer of a license combined with performance of research and development activities. The Company concluded that the license is not distinct in the context of the contract. · The transaction price of these two agreements is currently composed of a fixed part, that being an upfront license fee, and a variable part, being milestone payments and cost reimbursements of research and development activities delivered. Milestone payments are only included in the transaction price to the extent it is highly probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associate with the variable consideration is subsequently resolved. We estimate the amount to be included in the transaction price upon achievement of the milestone event. Sales-based milestones and sales-based royalties are a part of the Company’s arrangements but are not yet included in its revenues. · The transaction price has been allocated to the single performance obligation and revenues have been recognized over the estimated service period based on a pattern that reflects the transfer of the license and progress to complete satisfaction of the research and development activities. This is because we considered that there is a transformational relationship between the license and the research and development activities to be delivered. · The Company has chosen an input model to measure the satisfaction of the single performance obligation that considers percentage of costs incurred for these programs that are completed each period (percentage of completion method). · Cost reimbursements received are recognized in revenues when costs are incurred and agreed by the parties, as the Company is acting as a principal in the scope of its stake of the research and development activities of its ongoing license and collaboration agreements. Janssen In December 2018, the Company entered into a collaboration agreement with Cilag GmbH International, an affiliate of Janssen, to jointly develop and commercialize cusatuzumab. The Company has granted Janssen a license to the cusatuzumab program to develop, manufacture and commercialize products. For the U.S., the granted commercialization license is co-exclusive with argenx, while outside the U.S., the granted license is exclusive. Janssen and argenx will assume certain development obligations, and will be jointly responsible for all research, development and regulatory costs relating to the products. argenx will be eligible to receive potentially up to $1.3 billion in development, regulatory and sales milestones, in addition to tiered royalties, ranging from the low double digits to the high teens. Janssen will be responsible for commercialization worldwide. argenx retains the option to participate in commercialization efforts in the US, where the companies have agreed to share royalties on a 50/50 basis, and outside the U.S., Janssen will pay sales royalties ranging from the low double digits to the high teens to argenx. Under the terms of the agreement, Janssen committed to an upfront payment of $500 million consisting of a license payment of $300 million and a $200 million equity investment in the Company by subscribing to 1,766,899 new shares at a price of €100.02 per share, including an issuance premium. The agreement became effective in January 2019 following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. In December 2019, the Company achieved the first development milestone, triggering a $25.0 million payment. With regard to this collaboration with Janssen, the Company concluded as follows: · There is one single performance obligation under IFRS 15, that being the transfer of a license combined with performance of research and development activities. The Company concluded that the license is not distinct in the context of the contract. · The Company concluded that the share premium that Janssen paid above the closing price on the day of entering into the investment agreement (being December 2, 2018) was paid because of the existing obligations to deliver development services under the terms of the collaboration agreement, and is therefore to be considered to be part of the overall consideration received. · The transaction price of these two agreements is currently composed of a fixed part, that being an upfront license fee, and a variable part, being milestone payments and cost reimbursements of research and development activities delivered. Milestone payments are only included in the transaction price to the extent it is highly probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associate with the variable consideration is subsequently resolved. We estimate the amount to be included in the transaction price upon achievement of the milestone event. Sales-based milestones and sales-based royalties are a part of the Company’s arrangements but are not yet included in its revenues. · The transaction price has been allocated to the single performance obligation and revenues have been recognized over the estimated service period based on a pattern that reflects the transfer of the license and progress to complete satisfaction of the research and development activities. This is because we considered that there is a transformational relationship between the license and the research and development activities to be delivered. · The Company has chosen an input model to measure the satisfaction of the single performance obligation that considers percentage of costs incurred for these programs that are completed each period (percentage of completion method). · Cost reimbursements received are recognized in revenues when costs are incurred and agreed by the parties, as the Company is acting as a principal in the scope of its stake of the research and development activities of its ongoing license and collaboration agreements. |
Other operating income
Other operating income | 12 Months Ended |
Dec. 31, 2020 | |
Other operating income | |
Other operating income | 17. Other operating income Year Ended December 31, (in thousands of €) 2020 2019 2018 Grants € 1,226 € 2,289 € 1,842 Research and development incentives 8,875 4,818 2,151 Payroll tax rebates 8,008 5,694 3,756 € 18,109 € 12,801 € 7,749 17.1 Grants The grant income is related to grants received from the Flanders Innovation and Entrepreneurship Agency. No conditions related to the above government grants were unfulfilled, nor were there any material contingencies related thereon at the date of the approval of these consolidated financial statements. 17.2 Research and development incentives The Company has accounted for a tax receivable of €8.9 million in the year ended December 31, 2020, compared to €4.8 and €2.2 million in the year ended December 31, 2019 and December 31, 2018, respectively, following a research and development tax incentive scheme in Belgium according to which the incentive will be refunded after a five year period, if not offset against the current tax payable over the period. 17.3 Payroll tax rebates The Company accounted for €8.0 million payroll tax rebates in the year ended December 31, 2020, compared to €5.7 and €3.8 million in the year ended December 31, 2019 and December 31, 2018, respectively, as a reduction in withholding income taxes for its highly qualified personnel employed in its research and development department. |
Segment reporting
Segment reporting | 12 Months Ended |
Dec. 31, 2020 | |
Segment reporting | |
Segment reporting | 18. Segment reporting The Company operates from the Netherlands, Belgium, the United States of America and Japan. Revenues are generated by external customers with their main registered office geographically located as shown in the table below. In prior periods this has been presented based on the geographical location of the contracting entity. Revenue from external customers Year ended December 31, (in thousands of €) 2020 2019 2018 Denmark € 299 € 436 € 1,136 Belgium — 1,499 — United States 36,126 67,848 18,964 Other — — 1,382 Total € 36,425 € 69,783 € 21,482 The non-current assets of the Company, with the exception of the deferred tax assets, are geographically located as shown in the table below: Non-current assets Year ended December 31, (in thousands of €) 2020 2019 2018 Netherlands € 1 € 1 € 1 Belgium 163,224 56,777 5,967 United States 3,872 3,058 47 Japan 2,030 284 — Total € 169,127 € 60,120 € 6,015 |
Research and development expens
Research and development expenses | 12 Months Ended |
Dec. 31, 2020 | |
Research and development expenses | |
Research and development expenses | 19. Research and development expenses Year Ended December 31, (in thousands of €) 2020 2019 2018 Personnel expense € 75,121 € 45,733 € 26,519 External research and development expenses 228,438 137,050 48,859 Materials and consumables 3,099 2,027 1,464 Depreciation and amortization 2,472 1,641 494 Other expenses 16,349 11,214 6,273 € 325,479 € 197,665 € 83,609 |
Selling, general and administra
Selling, general and administrative expenses | 12 Months Ended |
Dec. 31, 2020 | |
Selling, general and administrative expenses | |
Selling, general and administrative expenses | 20. Selling, general and administrative expenses Year Ended December 31, (in thousands of €) 2020 2019 2018 Personnel expense € 94,251 € 40,082 € 18,292 Consulting fees 42,459 16,343 5,472 Supervisory board 4,243 2,792 1,088 Other Expenses 8,414 5,352 2,619 € 149,367 € 64,569 € 27,471 |
Personnel expenses
Personnel expenses | 12 Months Ended |
Dec. 31, 2020 | |
Personnel expenses | |
Personnel expenses | 21. Personnel expenses The personnel expenses mentioned in note 19 and 20 above are as follows: Year Ended December 31, (in thousands of €) 2020 2019 2018 Short‑term employee benefits—Salaries € 65,516 € 32,866 € 18,617 Short‑term employee benefits—Social Security 7,848 3,555 2,213 Post‑employment benefits 1,072 748 441 Termination benefits 849 644 96 Share‑based payment 80,644 37,208 18,527 Employer social security contributions stock options 13,443 10,794 4,918 € 169,372 € 85,815 € 44,812 The post‑employment benefits relate to the pension plans the Company has in place for its employees. The number of full‑time equivalents (FTE) employees by department is presented below: Year Ended December 31, Average Number of FTE 2020 2019 2018 Research and development 213.0 121.6 76.1 Selling, general and administrative 119.5 56.3 27.6 332.5 177.9 103.7 |
Leases
Leases | 12 Months Ended |
Dec. 31, 2020 | |
Leases | |
Leases | 22. Leases The statement of financial position shows the following amounts relating to leases: Year Ended December 31, December 31, In thousands of € 2020 2019 Right-of-use assets Buildings € 6,313 € 5,576 Vehicles 1,233 744 Equipment 215 243 € 7,760 € 6,563 Lease liabilities Current € 2,833 € 1,974 Non-current 5,035 4,540 € 7,868 € 6,514 Additions to the right-of-use assets amounted to €3.6 million for the year ended December 31, 2020. The table below shows a maturity analysis of the lease liabilities as on December 31, 2020: (in thousands of €) Less than 1 year 1-3 years 3-5 years More than 5 years Total contractual cash flows Carrying amount Lease liabilities € 3,043 € 4,085 € 1,171 € — € 8,299 € 7,868 The consolidated statements of profit or loss and other comprehensive income shows the following amounts relating to leases: Year Ended December 31, In thousands of € 2020 2019 2018 Depreciation charges Buildings € 1,981 € 1,315 € — Vehicles 386 233 — Equipment 28 28 11 € 2,395 € 1,576 € 11 Interest expense (included in finance cost) € 176 € 105 € — Expense relating to short-term leases 231 123 — Expense relating to leases of low-value assets that are not shown above as short-term leases 5 5 — The total cash outflow for leases in 2020 was €2.6 million. The Company did not enter into any lease agreement with variable lease payments or residual value guarantees. The Company has leases that include extension options. These options provide flexibility in managing the leased assets and align with the Company’s business needs. The Company exercises judgement in deciding whether it is reasonably certain that the extension options will be exercised. |
Financial result and exchange g
Financial result and exchange gains/(losses) | 12 Months Ended |
Dec. 31, 2020 | |
Financial result and exchange gains/(losses) | |
Financial result and exchange gains/(losses) | 23. Financial result and exchange gains/(losses) Year Ended December 31, (in thousands of €) 2020 2019 2018 Interest income € 4,517 € 7,874 € 1,371 Net gain on current financial assets held at fair value through profit or loss and cash equivalents 1,173 6,525 2,323 Financial income € 5,690 € 14,399 € 3,694 Net loss on current financial assets held at fair value through profit or loss and cash equivalents € (6,755) € — € Other financial expense (349) (124) — Financial expense € (7,104) € (124) € — Realized exchange gains/(losses) € (400) € (338) € 1,355 Unrealized exchange gains/(losses) (106,556) 6,404 10,953 Exchange gains/(losses) € (106,956) € 6,066 € 12,308 The exchange losses of €107.0 million for the year ended December 31, 2020 were primarily attributable to unrealized exchange rate gains on our cash and cash equivalents and current financial assets position in USD due to the unfavorable fluctuation of the USD exchange rate over the period. |
Income tax expense
Income tax expense | 12 Months Ended |
Dec. 31, 2020 | |
Income tax expense | |
Income tax expense | 24. The income tax expense for the year can be reconciled to the accounting loss as follows: Year Ended December 31, (in thousands of €) 2020 2019 2018 Loss before taxes € 526,139 € 158,213 € 65,847 Income tax calculated at 25% 131,535 39,553 16,462 Effect of expenses not deductible in determining taxable results (11,478) (7,701) (3,934) Effect of stock issue expenses that are not deductible in determining taxable results 11,775 5,750 3,716 Effect of concessions 6,804 572 430 Effect of tax losses carried forward not recognized (100,771) (11,670) (5,511) Effect of different tax rates in jurisdictions in which the company operates (168) (52) (15) Deferred tax asset other than loss carryforwards not recognized (39,516) (27,341) (11,968) (Underprovided)/overprovided in prior years (857) (3,876) Other (108) 13 26 Income tax expense recognized in the consolidated statement of profit and loss € (2,784) € (4,752) € (794) The tax rate used for the 2020, 2019 and 2018 reconciliations above is the corporate income tax rate of 25% payable by corporate entities in the Netherlands. The unrecognized deferred tax asset on deductible temporary differences and unused tax losses amounts to €141.9 million on December 31, 2020, comparefd to €40.0 million on December 31, 2019. Deferred tax have been measured using the effective rate that will apply in Belgium and the Netherlands (25%). The Company has unused tax losses carried forward for an amount of €567.8 million on December 31, 2020, compared to €160 million on December 31, 2019, of which €1.4 million and €7.2 million will expire in 2028 and 2029, respectively. This, combined with other temporary differences, resulted in a net deferred tax asset position. Due to the uncertainty surrounding the Company’s ability to realize taxable profits in the near future, the Company did not recognize any deferred tax assets, with the exception of those further detailed in note 10. Income taxes were directly recognized in the income statement can be detailed as follows: Year Ended December 31, (in thousands of €) 2020 2019 2018 Current year € 6,871 € 4,752 794 Income tax prior years 1,547 — — Current tax expense 8,418 4,752 794 Originating and reversal of temporary differences (5,634) — — Deferred tax expense / (income) (5,634) — — Total tax expense € 2,784 € 4,752 € 794 |
Loss per share
Loss per share | 12 Months Ended |
Dec. 31, 2020 | |
Loss per share | |
Loss per share | 25 . Year Ended December 31, (in thousands of €) 2020 2019 2018 Loss of the year € (528,923) € (162,965) € (66,641) Weighted average number of shares outstanding 45,410,442 38,619,121 33,419,356 Basic and diluted loss per share (in €) € (11.65) € (4.22) € (1.99) Earnings/losses per ordinary share are calculated by dividing the loss for the period by the weighted average number of ordinary shares during the year. As the Company reported a net loss in 2020, 2019 and 2018, stock options have an anti‑dilutive effect rather than a dilutive effect. As such, there is no difference between basic and diluted earnings/losses per ordinary share. |
Financial risk management
Financial risk management | 12 Months Ended |
Dec. 31, 2020 | |
Financial risk management | |
Financial risk management | 26. Financial risk management The financial risks are managed centrally. The Company coordinates the access to national and international financial markets and considers and manages continuously the financial risks concerning the Company’s activities. These relate to the financial markets risk, credit risk, liquidity risk and currency risk. There are no other important risks, such as interest rate risk on borrowings, as the Company has no financial debt. The Company does not buy or trade financial instruments for speculative purposes. Categories of financial assets and liabilities: Measurement category Carrying amount Year Ended December 31, (in thousands of €) 2020 2019 2018 Financial assets — non-current FVTPL € 5,140 € 2,596 € 1 Research and development incentive receivables — non-current Amortised cost 16,840 8,566 4,883 Restricted cash — non-current Amortised cost 1,243 630 251 Trade and other receivables Amortised cost 5,687 28,115 2,886 Financial assets—current FVTPL 635,359 1,004,539 283,529 Research and development incentive receivables — current Amortised cost 377 261 301 Restricted cash — current Amortised cost — — 1,692 Cash and bank balances Amortised cost 242,161 103,731 63,589 Cash equivalents FVTPL 699,447 — — Cash equivalents Amortised cost 50,001 227,551 217,451 Trade and other payables Amortised cost 224,262 85,301 37,072 The carrying amounts of trade and other payables are considered to be the same as their fair values, due to their short-term nature. Financial assets held at fair value through profit or loss Financial assets held at fair value through profit or loss consisted of equity instruments of listed and non-listed companies and money market funds. The Company has no restrictions on the sale of these equity instruments and the assets are not pledged under any of its liabilities. These instruments are classified as financial assets held at fair value through profit or loss which qualify for: · Level 1 fair value measurement with respect to current financial assets and cash equivalents based upon the closing price (net asset value) of such securities at each reporting date. · Level 3 fair value measurement with respect to non-current financial assets. The market price of these financial instruments might face fluctuations and might be affected by a variety of factors, such as the global economic situation. Current financial assets and cash equivalents include collective investment funds nominated in € and $ of which the underlying investments include bonds and other international debt securities. Based on the average credit rating of the underlying instruments, amongst others, these investments are either classified as current financial assets or cash equivalents. The maximum exposure to credit risk is the carrying amount at reporting date. The Company carried the following assets at fair value on December 31, 2020, 2019 and 2018 respectively: At December 31, 2020 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 5,140 Current financial assets 635,359 — — Cash Equivalents 699,447 — — Assets carried at fair value € 1,334,806 € — € 5,140 At December 31, 2019 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 2,596 Current financial assets 1,004,539 — — Assets carried at fair value € 1,004,539 € — € 2,596 At December 31, 2018 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 1 Current financial assets 283,529 — — Assets carried at fair value € 283,529 € — € 1 During the disclosed calendar year no transfers occurred between the applicable categories. In March 2019, the Company entered into a license agreement with AgomAb Therapeutics NV for the use of HGF-mimetic SIMPLE Antibodies™, developed under the Company’s Innovative Access Program. In exchange for granting this license, the Company received a profit share in AgomAb Therapeutics NV. The profit share has been designated as a non-current financial asset held at fair value through profit or loss. Since AgomAb Therapeutics NV is a private company, the valuation of the profit share is based on level 3 assumptions. Capital risk The Company manages its capital to ensure that it will be able to continue as a going concern. The capital structure of the Company consists of equity attributed to the holders of equity instruments of the Company, such as capital, reserves and accumulated losses as mentioned in the consolidated statement of changes in equity. The Company makes the necessary adjustments in the light of changes in the economic circumstances, risks associated to the different assets and the projected cash needs of the current and projected research activities. On December 31, 2020, cash and cash equivalents amounted to €991.6 million and total capital amounted to €2,062.9 million. The current cash situation and the anticipated cash generation are the most important parameters in assessing the capital structure. The Company’s objective is to maintain the capital structure at a level to be able to finance its activities for at least twelve months. Cash income from existing and new partnerships is taken into account and, if needed and possible, the Company can issue new shares or enter into financing agreements. Credit risk Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in financial loss to the Company. The Company has adopted a policy of only dealing with creditworthy counterparties and obtaining sufficient collateral, where appropriate, as a means of mitigating the risk of financial loss from defaults. Concentrations in credit risk are determined based on an analysis of counterparties and their importance on the overall outstanding contractual obligations at year end. The Company has a limited number of license and collaboration partners and therefore has a significant concentration of credit risk. However, it has policies in place to ensure that credit exposure is kept to a minimum and significant concentrations of credit exposure are only granted for short periods of time to high credit quality collaboration partners. The Company applied the IFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all receivables. To measure the expected credit losses, receivables have been grouped based on credit risk characteristics and the days past due. The provision for expected credit losses was not significant given that there have been no credit losses over the last three years and the high quality nature of our customers. Cash and cash equivalents and current financial assets are invested with several highly reputable banks and financial institutions. The Company holds its cash and cash equivalents mainly with different banks which are independently rated with a minimum rating of ‘A-’. The Company also holds short term investment funds in the form of money market funds with a recommended investment horizon of 6 months or shorter but with a low historical volatility. These money market funds are highly liquid investments, can be readily convertible into a known amount of cash. Since they are a basket of funds there is no individual credit risk involved. The average credit rating of the underlying instruments for the investment funds is “BBB-“ or higher. Liquidity risk The Company manages liquidity risk by maintaining adequate reserves, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. The Company’s main sources of cash inflows are obtained through capital increases and collaboration agreements. This cash is invested in savings accounts, term accounts and short term investment funds in the form of money market funds. These money market funds represent the majority of the Company’s available sources of liquidity however since all of these are immediately tradable and convertible in cash they have a limited impact on the liquidity risk. Interest rate risk The only variable interest-bearing financial instruments are cash and cash equivalents and current financial investments. Changes in interest rates may cause variations in interest income and expense resulting from short-term interest-bearing assts. Management does not expect the short-term interest rates to decrease significantly in the immediate foreseeable future, which limits the interest exposure on our cash and cash equivalents and current financial investments. For the year ended December 31, 2020, if applicable interest rates would increase/decrease by 25 basis points, this would have a positive/negative impact of €1.5 million (compared to €2.0 million for the year ended December 31, 2019 and €0.3 million for the year ended December 31, 2018). Foreign exchange risk The Company undertakes transactions denominated in foreign currencies; consequently, exposures to exchange rate fluctuations arise. The Company is mainly exposed to the U.S. Dollar, Japanse yen, British pound and Swiss franc. To limit this risk, the Company attempts to align incoming and outgoing cash flows in currencies other than EUR. The net exposure to exchange differences of the monetary assets (being cash, cash equivalents and current financial assets) of the Company at the end of the reporting period are as follows: At December 31, (in thousands of €) 2020 2019 2018 USD 1,053,803 821,916 312,831 JPY 215 488 — GBP 39 4 2 CHF 94 1 4 On December 31, 2020, if the USD/EUR exchange rate would have increased/decreased by 10%, this would have had a negative/positive impact of €95.80 million, compared to €74.72 million and €28.44 million on December 31, 2019 and December 31, 2018, respectively. On December 31, 2020, if the exchange rate for other currencies would have increased/decreased by 10% , this would have had no significant impact. |
Related party transactions
Related party transactions | 12 Months Ended |
Dec. 31, 2020 | |
Related party transactions | |
Related party transactions | 27. Related party transactions 27.1 Relationship and transactions with subsidiaries See note 31 for an overview of the consolidated companies of the group, which are all wholly-owned subsidiaries of argenx SE. Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. 27.2 Relationship and transactions with key personnel The Company’s key management personnel consists of the members of the management team and the members of the board of directors. Remuneration of key management personnel On December 31, 2020, the executive committee consisted of 9 members: Chief Executive Officer, Chief Operating Officer, Chief Financial Officer, Chief Scientific Officer, General Counsel, Chief Medical Officer, Vice President Corporate Development and Strategy, Global Head of Quality Assurance and Global Head of Human Resources. They provide their services on a full-time basis. On December 31, 2020, the board of directors consisted of 8 members: Peter Verhaeghe, Don deBethizy, Pamela M. Klein, David L. Lacey, Werner Lanthaler, A.A. Rosenberg, James M. Daly and Tim Van Hauwermeiren. Only the Chief Executive Officer is a member of both the management team and the board of directors. The Chief Executive Officer does not receive any special remuneration for his board membership, as this is part of his total remuneration package in his capacity as member of the management team. The remuneration package of the members of key management personnel comprises: Year Ended December 31, (in thousands of €, except for the number of stock options) 2020 2019 2018 Remuneration of key management personnel Short-term benefits for executive team members as a group Gross salary € 2,842 € 2,527 € 2,505 Variable pay 1,322 975 1,078 Employer social security 659 813 528 Other short term benefits 137 122 125 Termination Benefits 337 470 — Post-employment benefits for executive team members as a group 141 144 153 Cost of stock options granted in the year for executive team members as a group 37,493 21,847 13,363 Employer social security cost related to stock options 9,811 9,160 2,793 Total benefits for key management personnel 52,742 36,058 20,544 Numbers of stock options granted in the year Executive team as a group Remuneration of non-executive directors Board fees and other short-term benefits for directors 355 378 355 Cost of stock options granted in the year for non-executive directors 8,384 4,330 3,271 Total benefits for non-executive board members 8,739 4,708 3,626 Numbers of stock options granted in the year Non-executive directors 70,000 — 70,000 85,000 Other No loans, quasi-loans or other guarantees were given by the Company or any of its subsidiaries to members of the board of directors or the executive team. We have not entered into transactions with our key management personnel, other than as described above with respect to remuneration arrangements relating to the exercise of their mandates as members of the executive team and the board of directors. |
Contingencies
Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Contingencies | |
Contingencies | 28. Contingencies The Company is currently not facing any outstanding claims or litigations that may have a significant adverse impact on the Company’s consolidated financial position |
Commitments
Commitments | 12 Months Ended |
Dec. 31, 2020 | |
Commitments | |
Commitments | 29 . At balance sheet date, there were no commitments signed for the acquisition of property, plant and equipment. In January 2021, the Company entered into a binding lease commitment related to the envisioned relocation to a newly built office in Zwijnaarde, Belgium. Included in the binding lease commitment is a rent free period for 6 months following the completion of the building. The total future cash outflows related to this lease are as follows: (in thousands of €) Less than 1 year 1-3 years 3-5 years More than 5 years Total contractual cash flows Lease commitments not commenced € — € 282 € 3,382 € 13,247 € 16,912 In February 2019, and as amended in September 2020, the Company entered into a global collaboration and license agreement with Halozyme Therapeutics, Inc. Under the terms of the agreement, the Company will pay $12.5 million per target for future target nominations and potential future payments of up to $160.0 million per selected target subject to achievement of specified development, regulatory and sales-based milestones and up to $40.0 million subject to the achievement of additional, specified sales-based milestones. This amount represents the maximum amount that would be paid if all milestones would be achieved but excludes variable royalty payments based on unit sales. In 2019, the Company exercised the option to nominate an additional target (triggering a $10.0 million development milestone payment) and initiated a Phase 1 clinical trial using Halozyme's proprietary ENHANZE® drug delivery technology (triggering a $5.0 million development milestone payment). In 2020, the Company initiated a Phase 3 clinical trial using Halozyme’s proprietary ENHANZE® drug delivery technology (triggering a $15.0 million development milestone payment). The Company’s manufacturing commitments with Lonza, its drug substance manufacturing contractor, relate to the ongoing execution of the biologic license application (BLA) services for efgartigimod and its manufacturing activities related to the potential future commercialisation. In December 2018, the Company signed its first commercial supply agreement with Lonza related to the reservation of commercial drug substance supply capacity for efgartigimod. In the aggregate, the Company has outstanding commitments for efgartigimod under the first commercial supply agreement of €114.0 million. |
Audit fees
Audit fees | 12 Months Ended |
Dec. 31, 2020 | |
Audit fees | |
Audit fees | 30. Audit fees The following auditors’ fees were expensed in the income statement: Year Ended December 31, Fees 2020 2019 2018 in thousands of € Audit fees (1) € 808 € 730 € 648 Audit-related fees 165 159 143 Tax and other services (2) — — — Total € 973 € 889 € 791 (1) Audit services performed by Deloitte Accountants B.V. as the external auditor referred to in Section 1 of the Dutch Accounting Firms Oversight Act (Wta) as well as by the Deloitte network. (2) Tax and other services performed by the Deloitte network. |
Overview of consolidation scope
Overview of consolidation scope | 12 Months Ended |
Dec. 31, 2020 | |
Overview of consolidation scope | |
Overview of consolidation scope | 31. The parent company argenx SE is domiciled in the Netherlands. The Company, argenx SE, has two subsidiaries, argenx BV and argenx IIP BV, based in Belgium. argenx BV has three subsidiary, argenx US, Inc., based in the United States of America, argenx Japan KK, based in Japan and argenx Switzerland SA, based in Switzerland. Details of the Company’s consolidated entities at the end of the reporting period are as follows: Name Registration number Country Participation Main activity argenx SE COC 24435214 The Netherlands 100.00 % Holding company argenx BV Belgium 100.00 % Biotechnical research on drugs and pharma processes argenx IIP BV Belgium 100.00 % Biotechnical research on drugs and pharma processes argenx US, Inc. 36-4880497 USA 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers argenx Switzerland, SA CH-660.3.799.020-7 Switzerland 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers argenx Japan KK 0104-01-145183 Japan 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers 8. |
Events after the balance sheet
Events after the balance sheet date | 12 Months Ended |
Dec. 31, 2020 | |
Events after the balance sheet date | |
Events after the balance sheet date | 32. Events after the balance sheet date On January 6, 2021, argenx and Zai Lab announced a Strategic Collaboration for efgartigimod in Greater China, expected to allow the Company to more rapidly advance new potential indications into clinical development each year and grants Zai Lab the exclusive rights to develop and commercialize efgartigimod in Greater China. Zai Lab will recruit Chinese patients to argenx’s registrational trials for the development of efgartigimod and will allow argenx to accelerate efgartigimod development by initiating multiple Phase 2 proof-of-concept trials in new autoimmune indications. Under the terms of the agreement, the Company will receive up to $175 million in collaboration payments, comprised of a $75 million upfront payment in the form of 568,182 newly issued Zai Lab shares calculated at a price of $132 per share, $75 million as guaranteed non-creditable, non-refundable payment, and an additional $25 million milestone payment upon approval of efgartigimod in the U.S. The Company is also eligible to receive tiered royalties (mid-teen to low twenties on a percentage basis) based on annual net sales of efgartigimod in Greater China. In January 2021, the Company entered into a binding lease commitment in relation to the envisioned relocation to a newly built office for an annual base rent of €1.7 million which would be operational in the second quarter of 2023, and has an initial term of 10.5 years. Included in the binding lease commitment is a rent free period for 6 months following the completion of the building. On February 5, 2021, argenx SE announced the closing of their global offering of 3,125,000 of its ordinary shares through a global offering which consisted of (i) a public offering of 1,608,000 ADSs in the U.S. and certain other countries outside the European Economic Area (EEA) at a price of $320.00 per ADS, before underwriting discounts and commissions, and offering expenses; and (ii) a concurrent private placement of 1,517,000 ordinary shares in the European Economic Area at a price of €265.69 per share, before underwriting discounts and commissions, and offering expenses. On February 4, 2021, the underwriters of the offering exercised their over-allotment option to purchase 468,750 additional ADSs in full. As a result, the Company received €954.8 million in gross proceeds from the offering, decreased by €46.8 million of underwriter discounts and commissions, and offering expenses, of which €46.5 million is expected to be deducted from equity. The total net cash proceeds from the offering amounted to €908.0 million. |
Significant accounting polici_2
Significant accounting policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Significant accounting policies | |
Statement of compliance and basis of preparation | 3.1 Statement of compliance and basis of preparation The consolidated financial statements are prepared in accordance with the International Financial Reporting Standards (IFRS), issued by the International Accounting Standards Board (IASB) and the interpretations issued by the IASB’s International Financial Reporting Interpretation Committee. The consolidated financial statements provide a general overview of the Company’s activities and the results achieved. They present fairly the entity’s financial position, its financial performance and cash flows, on a going concern basis. The significant accounting policies applied in the preparation of the above consolidated financial statements are set out below. All amounts are presented in thousands of euro, unless otherwise indicated, rounded to the nearest € ‘000. The consolidated financial statements have been approved for issue by the Company’s Board of Directors (the Board) on March 30, 2021. |
Adoption of new and revised standards | 3.2 Adoption of new and revised standards New New standards and interpretations for the annual period beginning on January 1, 2020 did not have any material impact on our consolidated financial statements. New standards and interpretations issued, but not yet applicable for the annual period beginning on January 1, 2020 We have not early adopted any other standard, interpretation, or amendment that has been issued but is not yet effective; The following new standards and amendments to standards have been issued, but are not mandatory for the first time for the financial year beginning January 1, 2020 and have been endorsed by the European Union. Amendments to IFRS 10 and IAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture The amendments to IFRS 10 and IAS 28 deal with situations where there is a sale or contribution of assets between an investor and its associate or joint venture. Specifically, the amendments state that gains or losses resulting from the loss of control of a subsidiary that does not contain a business in a transaction with an associate or a joint venture that is accounted for using the equity method, are recognised in the parent’s profit or loss only to the extent of the unrelated investors’ interests in that associate or joint venture. Similarly, gains and losses resulting from the remeasurement of investments retained in any former subsidiary (that has become an associate or a joint venture that is accounted for using the equity method) to fair value are recognised in the former parent’s profit or loss only to the extent of the unrelated investors’ interests in the new associate or joint venture. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IFRS 3 – Reference to the Conceptual Framework The amendments update IFRS 3 so that it refers to the 2018 Conceptual Framework instead of the 1989 Framework . They also add to IFRS 3 a requirement that, for obligations within the scope of IAS 37, an acquirer applies IAS 37 to determine whether at the acquisition date a present obligation exists as a result of past events. For a levy that would be within the scope of IFRIC 21 Levies , the acquirer applies IFRIC 21 to determine whether the obligating event that gives rise to a liability to pay the levy has occurred by the acquisition date. Finally, the amendments add an explicit statement that an acquirer does not recognise contingent assets acquired in a business combination. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IAS 16 – Property, Plant and Equipment—Proceeds before Intended Use The amendments prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced before that asset is available for use, i.e. proceeds while bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Consequently, an entity recognises such sales proceeds and related costs in profit or loss. The entity measures the cost of those items in accordance with IAS 2 Inventories . The amendments also clarify the meaning of ‘testing whether an asset is functioning properly’. IAS 16 now specifies this as assessing whether the technical and physical performance of the asset is such that it is capable of being used in the production or supply of goods or services, for rental to others, or for administrative purposes. If not presented separately in the statement of comprehensive income, the financial statements shall disclose the amounts of proceeds and cost included in profit or loss that relate to items produced that are not an output of the entity’s ordinary activities, and which line item(s) in the statement of comprehensive income include(s) such proceeds and cost. The amendments are applied retrospectively, but only to items of property, plant and equipment that are brought to the location and condition necessary for them to be capable of operating in the manner intended by management on or after the beginning of the earliest period presented in the financial statements in which the entity first applies the amendments. The entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings (or other component of equity, as appropriate) at the beginning of that earliest period presented. These amendments are not expected to have any material impact on our consolidated financial statements. Amendments to IAS 37 – Onerous Contracts—Cost of Fulfilling a Contract The amendments specify that the ‘cost of fulfilling’ a contract comprises the ‘costs that relate directly to the contract’. Costs that relate directly to a contract consist of both the incremental costs of fulfilling that contract (examples would be direct labour or materials) and an allocation of other costs that relate directly to fulfilling contracts (an example would be the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract). The amendments apply to contracts for which the entity has not yet fulfilled all its obligations at the beginning of the annual reporting period in which the entity first applies the amendments. Comparatives are not restated. Instead, the entity shall recognise the cumulative effect of initially applying the amendments as an adjustment to the opening balance of retained earnings or other component of equity, as appropriate, at the date of initial application. These amendments are not expected to have any material impact on our consolidated financial statements. |
Basis of consolidation | 3.3 Basis of consolidation The consolidated financial statements include the financial statements of the Company and entities controlled by the Company (its subsidiaries). Control is achieved when the Company; · has power over the investee; · is exposed, or has rights, to variable returns from its involvement with the investee; and · has the ability to use its power to affect its returns. The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above. The results of the subsidiaries are included in the consolidated statements of profit and loss and other comprehensive income from the effective date of acquisition up to the date when control ceases to exist. When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with those used by other members of the Group. All inter-company transactions and unrealized gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. |
Foreign currency transactions | 3.4 Foreign currency transactions 3.4.1 Functional and presentation currency Items included in the consolidated financial statements of each of our entities are valued using the currency of their economic environment in which the entity operates. The consolidated financial statements are presented in euro (€), which is the Company’s presentation currency. 3.4.2 Transactions and balances Transactions in foreign currencies are translated at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date. Foreign exchange differences arising on translation are recognized in the consolidated statements of profit and loss and other comprehensive income. Non‑monetary assets and liabilities denominated in foreign currencies are translated at the foreign exchange rate ruling at the date of the transaction. 3.4.3 Financial statements of foreign entities For foreign entities using a different functional currency than euro: · assets and liabilities for each consolidated statements of financial position presented are translated at the closing rate at the date of that statement of financial position. · income and expenses for each statement presenting profit or loss and other comprehensive income are translated at average exchange rates (unless this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the rate on the dates of the transactions). · all resulting exchange differences are recognised in other comprehensive income. |
Intangible assets | 3.5 Intangible assets 3.5.1 Internally generated intangible assets Expenditure on research activities is recognized as an expense in the period in which it is incurred. An internally‑generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated: · the technical feasibility of completing the intangible asset so that it will be available for use or sale; · the intention to complete the intangible asset and use or sell it; · the ability to use or sell the intangible asset; · how the intangible asset will generate probable future economic benefits; · the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and · the ability to measure reliably the expenditure attributable to the intangible asset during its development. The amount initially recognized for internally‑generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally‑generated intangible asset can be recognized, development expenditures are recognized in the consolidated statements of profit and loss and other comprehensive income in the period in which they are incurred. Due to uncertainties inherent to the development and registration with the relevant healthcare authorities of its products, the Company estimates that the conditions for capitalization are not met until the regulatory procedures required by such healthcare authorities have been finalized. The Company currently does not own products that have been approved by the relevant healthcare authorities and this has resulted in all development costs being recognized as an expense in the period in which they are incurred. 3.5.2 Acquired In-Process R&D, Software and Databases and Other intangible assets Intangible assets with finite useful lives that are acquired separately related to in-process research and development projects, software and databases and other intangible assets are carried at cost less accumulated amortization and accumulated impairment losses. Intangible assets with indefinite useful lives are carried at cost less accumulated impairment losses. Payments for acquired in-process research and development projects obtained through in-licensing arrangements are capitalized as intangible assets provided that they are separately identifiable, controlled by the Company and expected to provide future economic benefits. As the probability criterion in IAS 38 is always considered to be satisfied for separately acquired research and development assets and the amount of the payments is determinable, upfront and milestone payments to third parties for pharmaceutical products or compounds for which regulatory marketing approval has not yet been obtained are recognized as intangible assets. Other intangible assets includes the Priority Review Voucher (“PRV”) acquired in 2020 which the Company can use to obtain the priority review by the FDA for one of its future regulatory submissions or may sell or transfer to a third party. The PRV is measured at cost and reviewed for impairment when events or circumstances indicate that the carrying value may not be recoverable. At the time the Company commits using the PRV to accelerate the review of a drug application, the intangible asset will be amortized and derecognized upon filing of the related Biologic License Application. 3.5.3 Amortization of intangible assets Intangible assets, which comprises of acquired in-process research and development, software and databases and other intangible assets, are amortized on a straight-line basis over the estimated useful life as from the time they are available for use, or when the underlying drug candidate is approved, generally on the following basis: · Acquired In-Process R&D – the longer of the patent protection life and the useful life of the combined product · Software and Databases – 3 – 5 years The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. 3.5.4 Derecognition of intangible assets An intangible asset is derecognized either on disposal or when no future economic benefits are expected from its use. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds, if any, and the carrying amount of the asset, are recognized in the consolidated statements of profit and loss and other comprehensive income when the asset is derecognized. |
Property, plant and equipment | 3.6 Property, plant and equipment Items of property, plant and equipment held for use in the production or supply of goods or services, or for administrative purposes, are stated in the statement of financial position at their cost, less accumulated depreciation and impairment losses. Depreciation is recognized as from acquisition date onwards (unless asset is not ready for use) so as to write off the cost or valuation of assets (other than freehold land and properties under construction) less their residual values over their useful lives, using the straight‑line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. Unless revised due to specific changes in the estimated useful life, annual depreciation rates are as follows: · Office and lab equipment: 3–5 years · IT equipment: 3 years An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference between the sales proceeds, if any, and the carrying amount of the asset and is recognized in the consolidated statements of profit or loss and other comprehensive income. |
Inventories | 3.7 Inventories Inventories are carried at cost or net realisable value, whichever is lowest. Cost is determined using the first-in, first-out method. Cost comprises of costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. If the expected sales price less completion costs to execute sales (net realizable value) is lower than the carrying amount, a write-down is recognised for the amount by which the carrying amount exceeds its net realisable value. Included in inventory are products which could, besides commercial activities, be used in preclinical and clinical programs as well as in non-reimbursed Early Access Programs. These products are charged to research & development expenses or selling, general and administrative expenses, respectively, when dedicated to this channel. We capitalize inventory costs associated with products prior to the regulatory approval of these products, or for inventory produced in new production facilities, when it is highly probable that the pre-approval inventories will be saleable. The determination to capitalize is based on the particular facts and circumstances relating to the expected regulatory approval of the product or production facility being considered. The assessment of whether or not the product is considered highly probable to be saleable is made on a quarterly basis and includes, but is not limited to, how far a particular product or facility has progressed along the approval process, any known safety or efficacy concern, potential labelling restrictions and other impediments. Previously capitalized costs related to pre-launch inventories could be required to be written down upon a change in such judgement or due to a denial or delay of approval by regulatory bodies, a delay in commercialization or other potential factors, which will be recorded to research and development expenses. |
Leases | 3.7 Leases As of January 1, 2019, the Company has changed its accounting policy for leases where the Company is the lessee. 3.8.1 Accounting policy until December 31, 2018 Leases of property, plant and equipment where the Company, as lessee, had substantially all the risks and rewards of ownership were classified as finance leases. Finance leases were capitalised at the lease’s inception at the fair value of the leased property or, if lower, the present value of the minimum lease payments. The corresponding rental obligations, net of finance charges, were included in other short-term and long-term payables. Each lease payment was allocated between the liability and finance cost. The finance cost was charged to the profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. The property, plant and equipment acquired under finance leases was depreciated over the asset’s useful life or over the shorter of the asset’s useful life and the lease term if there is no reasonable certainty that the Company will obtain ownership at the end of the lease term. Leases in which a significant portion of the risks and rewards of ownership were not transferred to the Company as lessee were classified as operating leases. Operating lease payments were recognized as an expense on a straight‑line basis over the lease term, except where another systematic basis was more representative of the time pattern in which economic benefits from the leased asset are consumed. The Company has adopated IFRS 16 on January 1, 2019. The Company elected to apply the modified retrospective approach for the transition, which foresees that prior period figures remain as reported under the previous standard IAS 17, and the cumulative effect of applying IFRS 16 is recognized as an adjustment to the opening balance of equity as of the date of initial application (i.e., the beginning of the year 2019). On adoption of IFRS 16, the Company recognized lease liabilities in relation to leases which had previously been classified as ‘operating leases’ under IAS 17. These liabilities were measured at the present value of the remaining lease payments and discounted using the Company’s incremental borrowing rate as of January 1, 2019. The Company’s weighted average incremental borrowing rate applied to these lease liabilities on January 1, 2019 was 1.32%. The differences between our total operating lease commitments as reported in note 5.7 of our consolidated financial statements of December 31, 2018 and the total lease liabilities recognized in our statement of financial position as at January 1, 2019 are summarized below: (in thousands of €) Operating lease commitments disclosed as at December 31, 2018 € 3,004 Less: discounting effect using the lessee's incremental borrowing rate of the date of initial application € (126) Less: short-term leases recognized on a straight-line basis as expense € (88) Lease liability recognized as at January 1, 2019 € 2,790 of which are: Current lease liabilities € 1,078 Non-current lease liabilities € 1,712 The cumulative effect of adopting IFRS 16 to the consolidated statements of financial position as of January 1, 2019 is as follows: (in thousands of €) Property, plant and equipment (right-of-use assets) € 2,790 Effect on total assets € 2,790 Lease liabilities (current and non-current) € 2,790 Effect on total equity and liabilities € 2,790 The Company has elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4 Determining whether an Arrangement contains a Lease . 3.8.2 Accounting policy as from January 1, 2019 As from January 1, 2019, the Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the lessee uses its incremental borrowing rate. The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made. The lease liability is presented as a separate line in the consolidated statements of financial position. The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses. Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The right-of-use assets are presented in the consolidated statements of financial position under the caption “Property, plant and equipment”. |
Impairment of assets | 3.9 Impairment of assets 3.9.1 Financial Assets The impairment loss of a financial asset measured at amortised cost is calculated based on the expected loss model. For trade receivables, in the absence of a significant financing component, the allowance is measured at an amount equal to lifetime expected credit losses. Those are the expected credit losses that result from possible default events over the expected life of those trade receivables. 3.9.2 Property, plant and equipment and intangible assets At the end of each reporting period, the Company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. Where it is not possible to estimate the recoverable amount of an individual asset, the Company estimates the recoverable amount of the cash‑generating unit to which the asset belongs. Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that the asset may be impaired. If the recoverable amount of an asset or cash‑generating unit is estimated to be less than its carrying amount, the carrying amount of the asset or cash‑generating unit is reduced to its recoverable amount. An impairment loss is recognized immediately in the statement of profit or loss and other comprehensive income. Where an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset or cash‑generating unit in prior years. A reversal of an impairment loss is recognized immediately in profit or loss. |
Financial instruments | 3.10 Financial instruments Financial assets and financial liabilities are recognized in the consolidated statements of financial position when the Company becomes party to the contractual provisions of the instrument. The Company does not use currency derivatives to hedge planned future cash flows, nor does it make use of forward foreign exchange contracts. Additionally, the Company does not have financial debt at December 31, 2020. 3.10.1 Financial assets Financial assets are initially recognized either at fair value or at transaction price. All recognized financial assets are subsequently measured at either amortized cost or fair value under IFRS 9 on the basis of both the Company’s model for managing the financial assets and the contractual cash flow characteristics of the financial asset. · A financial asset that (i) is held within a business model whose objective is to collect the contractual cash flows and (ii) has contractual cash flows that are solely payments of principal and interest on the principal amount outstanding is measured at amortized cost (net of any write down for impairment), unless the asset is designated at fair value through profit or loss (FVTPL) under the fair value option. · A financial asset that (i) is held within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets and (ii) has contractual term that give rise on specified dates to cash flows that are solely payments of principal and interest on the principal outstanding, is measured at fair value through other comprehensive income (FVTOCI), unless the asset is designated at FVTPL under the fair value option. · All other financial assets are measured at FVTPL. A financial asset is classified as current when the cash flows expected to flow from the instrument mature within one year. The Company derecognized a financial asset when the contractual rights to the cash flows from the asset expire, or the Company transfers the right to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. The Company classifies non-derivative financial assets into the following categories; · financial asset at fair value through profit or loss (non-current financial assets, current financial assets and cash equivalents) · financial assets at amortized cost (receivables and cash and cash equivalents) Financial assets at fair value through profit or loss Financial assets are designated at fair value through profit or loss if the Company manages such investments and makes purchases and sales decisions based on their fair value in accordance with the Company’s investment strategy. Attributable transaction costs are recognised in the consolidated statements of profit or loss and other comprehensive income as incurred. Financial assets at fair value through profit or loss are measured at fair value, and changes therein, which take into account any dividend income, are recognized in the consolidated statements of profit or loss and other comprehensive income. 3.10.1.1 Non-current financial assets The Company holds investments in non-current financial assets, which based on IFRS 9, are designated as financial assets at fair value through profit or loss, which qualify for level 3 fair value measurement based on current market prices. If the market for a financial asset is not active (and for unlisted securities), the Company established fair value by using valuation techniques. 3.10.1.2 Current financial assets Current financial assets include financial assets measured at fair value through profit or loss and comprise of money market funds and term accounts that have an initial maturity equal or less than 12 months, but exceeding 3 months. 3.10.1.3 Cash equivalents measured at fair value through profit or loss Cash equivalents measured at fair value through profit or loss may comprise of term accounts that have an initial maturity of equal or less than 3 months and money market funds that are readily convertible to cash and are subject to insignificant risk of changes in value. These financial assets are used by the Company in the management of the short-term commitments. Financial assets at amortized cost 3.10.1.4. Receivables Trade and other receivables are designated as financial assets measured at amortized cost. They are initially measured either at fair value or at transaction price, in the absence of a significant financing component. All receivables are subsequently measured at amortized cost, which generally corresponds to nominal value less expected credit loss provision. Receivables mainly comprise trade and other receivables and current and non-current research and development incentive receivables. These research and development incentive receivables relate to refunds resulting from research and development incentives on research and development expenses in Belgium and are credited to the consolidated statements of profit or loss and other comprehensive income under the line “Other operating income” when the relevant expenditure has been incurred and there is a reasonable assurance that the research and development incentives are receivable. 3.10.1.5 Cash Cash are financial assets measured at amortized cost and comprise of cash balances and savings accounts. 3.10.1.6 Cash equivalents measured at amortized costs Cash equivalents measured at amortized cost comprise of term accounts that have an initial maturity of less than 3 months that are subject to an insignificant risk of changes in values. The financial assets are used by the Company in the management of short-term commitments. Cash and cash equivalents exclude restricted cash, which is presented in the consolidated statements of financial position under the line “Restricted cash – current” and “Other non-current assets”. 3.10.2 Financial Liabilities Financial liabilities are initially measured at their transaction price. Subsequent to initial recognition, financial liabilities are measured at amortized cost. Financial liabilities mainly comprise of trade and other liabilities. Trade and other liabilities are comprised of liabilities that are due less than one year from the balance sheet date and are in general not interest bearing and settled on an ongoing basis during the financial year. They also include accrued expense related to the Company’s research and development costs. |
Shareholder's equity | 3.11 Shareholder’s equity An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs. The Company has never distributed any dividends to its shareholders. As of December 31, 2020, no profits were available for distribution. |
Provisions | 3.12 Provisions Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (where the effect of the time value of money is material). |
Retirement benefits | 3.13 Retirement benefits 3.13.1 Defined contribution plans Contributions to defined contribution pension plans are recognized as an expense in the consolidated statements of profit or loss and other comprehensive income as incurred. 3.13.2 Defined benefit plans For defined retirement benefit plans, the cost of providing benefits is determined using the projected unit credit method, with actual valuations being carried out at the end of each annual reporting period. Remeasurement, comprising actuarial gains and losses, the effect of the changes to the asset ceiling (if applicable) and the return on plan assets (excluding interest), is reflected immediately in the consolidated statements of financial position with a charge or credit recognized in other comprehensive income in the period in which they occur. Remeasurement recognized in other comprehensive income is reflected immediately in retained earings and will not be reclassified to profit or loss. Past service cost is recognized in the consolidated statements of profit or loss and other comprehensive income in the period of a plan amendment. Net interest is calculated by applying the discount rate at the beginning of the period to the net defined benefit liability or asset. Defined benefit costs are categorized as follows: service costs (including current service cost, past service cost, as well as gains and losses on curtailments and settlements), net interest expenses or income, and remeasurement. The retirement benefit obligation recognized in the consolidated statements of financial position represents the actual deficit or surplus in the defined benefit plans. Any surplus resulting from this calculation is limited to the present value of any economic benefits available in the form of refunds from the plans or a reduction in future contribution to the plans. A liability for a termination benefit is recognized at the earlier of when we can no longer withdraw the offer of the termination benefit and when we recognize any related restructuring costs. |
Research and development cost accruals | Research and development cost accruals The Company recognizes costs of €52.6 million, as specified in note 15 to the financial statements, incurred for clinical trial activities and manufacturing of drug products, as research and development expenses based on an evaluation of its vendors’ progress toward completion of specific tasks. Timing of payment may differ significantly from the period in which the costs are recognized as expense, resulting in clinical trial accruals recognized within “Trade and other payables” in the consolidated statements of financial position. Quantification of the research progress and the translation of the progress to these accruals requires estimates, because the progress is not directly observable. In estimating the vendors’ progress toward completion of specific tasks, the Company therefore uses non-financial data such as patient enrollment, clinical site activations and vendor information of actual costs incurred. This data is obtained through reports from or discussions with Company personnel and outside service providers as to the progress or state of completion of trials, or the completion of services. Costs are expensed over the service period the services are provided. Costs for services provided that have not yet been paid are recognized as accrued expenses. Research and development cost accruals directly impact the revenue recognized, given the satisfaction of the single performance obligation is measured using the input method. |
Short-term employee benefits | 3.14 Short‑term employee benefits Short‑term employee benefits include payables and accruals for salaries and bonuses to be paid to the employees of the Company. They are recognized as expenses for the period in which employees perform the corresponding services. |
Share-based payments | 3.15 Share‑based payments Equity‑settled share‑based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the acceptance date. The fair value determined at the acceptance date of the equity‑settled share‑based payments is expensed on a straight‑line basis over the vesting period, based on the Company’s estimate of equity instruments that will eventually vest, with a corresponding increase in equity. At the end of each reporting period, the Company revises its estimate of the number of equity instruments expected to vest. The impact of the revision of the original estimates, if any, is recognized in the consolidated statements of profit or loss and other comprehensive income such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the equity‑settled share‑based payment reserve. |
Deferred revenue | 3.16 Deferred revenue Current and non-current deferred revenue relates to cash received from collaboration & license agreements prior to completion of the earnings process. These payments are recognized as revenue over the estimated duration of the Company’s involvement in the research and development programs provided for under the terms of the agreements. |
Income taxes | 3.17 Income taxes Income tax in the consolidated statements of profit or loss and other comprehensive income represents the sum of the current tax and deferred tax. The current tax is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of profit and loss and other comprehensive income as it excludes items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax basis used in the computation of taxable profit. Deferred tax assets are recognized to the extent that it is probable that future taxable profits will be available against which those deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different taxable entities which intend either to settle current tax liabilities and assets on a net basis, or to realize the assets and settle the liabilities simultaneously. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantially enacted by the end of the reporting period. |
Revenue and other operating income recognition | 3.18 Revenue and other operating income recognition 3.18.1 Collaborations and license agreements Revenues to date have consisted principally of milestones, license fees, non-refundable upfront fees and research and development service fees in connection with collaboration and license agreements. The Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods and services. In order to determine revenue recognition for agreements that the Company determines to be in the scope of IFRS 15, following five steps are performed: 1. Identify the contracts In its current collaboration and license agreements, the Company is mainly licensing its intellectual property and/or providing research and development services, which might include a cost sharing mechanism and/or in the future, selling its products to collaborative partner entities. Revenue is generated through these arrangements via upfront payments, milestone payments based on clinical and regulatory criteria, research and development service fees and future sales based milestones and sales based royalties. In some cases the collaboration and license agreements also include an equity subscription component. If this is the case, the Company analyses if the criteria to combine contracts, as set out by IFRS 15, are met. 2. Identify performance obligations Depending on the type of the agreement, there can be one or more distinct performance obligations under IFRS 15. This is based on an assessment of whether the promises in an agreement are capable of being distinct and are distinct from the other promises to transfer goods and/or services in the context of the contract. The Company has assessed that there is one single performance obligation in our material ongoing collaboration and license agreements, being the transfer of a license combined with performance of research and development services. This is because the Company considers the performance obligations cannot be distinct in the context of the contract as the license has no stand-alone value without the Company being further involved in the research and development collaboration and that there is interdependence between the license and the research and development services to be provided. 3. Determine the transaction price Our material ongoing collaboration and license agreements include non-refundable upfront payments or license fees; milestone payments, the receipt of which is dependent upon the achievement of certain clinical, regulatory or commercial milestones; royalties on sales and research and development service fees. 3.1 Non-refundable upfront payments or license fees If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable upfront fees allocated to this license at the point in time the license is transferred to the customer and the customer has the right to use the license. For all our material ongoing collaboration and license agreements, the Company considers the performance obligations related to the transfer of the license as not distinct from the other promises to transfer goods and/or services; the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. If over time, revenue is then recognized based on a pattern that best reflects the transfer of control of the service to the customer. 3.2 Milestone payments other than sales based milestones A milestone payment, being a variable consideration, is only included in the transaction price to the extent it is highly probable that a significant reversal in the amount of cumulative revenue recognition will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company estimates the amount to be included in the transaction price upon achievement of the milestone event. The transaction price is then allocated to each performance obligation on a stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and, if necessary, adjusts the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment. 3.3 Research and development service fees Our material ongoing collaboration and license agreements may include reimbursement or cost sharing for research and development services. R&D services are performed and satisfied over time given that the customer simultaneously receives and consumes the benefits provided by us. Such costs reimbursements received are recognized in revenues when costs are incurred and agreed by the parties. 3.4 Sales based milestone payments and royalties Our material ongoing collaboration and license agreements include sales based royalties, including commercial milestone payments based on the level of sales, and the license has been deemed to be the predominant item to which the royalties and commercial milestone payments relate. Related revenue is recognized as the subsequent underlying sales occur. 4. Allocate the transaction price In principle, an entity shall allocate the transaction price to each performance obligation identified in the contract on a relative stand-alone selling price basis. As our ongoing license and collaboration arrangements only contain one single performance obligation, the transaction price is entirely allocated to this single performance obligation. 5. Recognize revenue Revenue is recognized when the customer obtains control of the goods and/or services as provided in the collaboration and license agreements. The control can be transferred over time or at a point in time – which results in the recognition of revenue over time or at a point in time. As our ongoing license and collaboration arrangements only contain one single performance obligation which is, as the customer simultaneously receive the benefits provided by the Company’s performance, satisfied over time, the Company recognizes revenue over time. The recognition of revenue over time is based on a pattern that best reflects the satisfaction of the related performance obligation, applying the input method. The input method estimates the satisfaction of the performance obligation as the percentage of total collaboration costs that are completed each period compared to the total estimated collaboration costs. Research and development service fees are recognized as revenue when costs are incurred and agreed by the parties as the Company is acting as a principal in the scope of its stake of the research and development activities of its ongoing collaboration and license agreements. 3.18.2 Grants, research and development incentives and payroll tax rebates Because it carries out extensive research and development activities, the Company benefits from various grants, research and development incentives and payroll tax rebates from certain governmental agencies. These grants, research and development incentives and payroll tax rebates generally aim to partly reimburse approved expenditures incurred in research and development efforts of the Company and are credited to the consolidated statements of profit and loss and other comprehensive income, under the line “Other operating income”, when the relevant expenditure has been incurred and there is reasonable assurance that the grants or research and development incentives are receivable. |
Segment reporting | 3.19 Segment reporting Segment results include revenue and expenses directly attributable to a segment and the relevant portion of revenue and expenses that can be allocated on a reasonable basis to a segment. Segment assets and liabilities comprise those operating assets and liabilities that are directly attributable to the segment or can be allocated to the segment on a reasonable basis. Segment assets and liabilities do not include income tax items. The Company manages its activities and operates as one business unit which is reflected in its organizational structure and internal reporting. The Company does not distinguish in its internal reporting different segments, neither business nor geographical segments. The chief operating decision‑maker is the Board of Directors. |
Significant accounting polici_3
Significant accounting policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Schedule of operating lease commitment to lease liabilities | (in thousands of €) Operating lease commitments disclosed as at December 31, 2018 € 3,004 Less: discounting effect using the lessee's incremental borrowing rate of the date of initial application € (126) Less: short-term leases recognized on a straight-line basis as expense € (88) Lease liability recognized as at January 1, 2019 € 2,790 of which are: Current lease liabilities € 1,078 Non-current lease liabilities € 1,712 |
IFRS 16 | |
Schedule of cumulative effect of adoption | (in thousands of €) Property, plant and equipment (right-of-use assets) € 2,790 Effect on total assets € 2,790 Lease liabilities (current and non-current) € 2,790 Effect on total equity and liabilities € 2,790 |
Intangible assets (Tables)
Intangible assets (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Intangible assets | |
Schedule of intangible assets | (in thousands of €) Acquired In-Process R&D Software & databases Other Intangibles Total Cost On January 1, 2018 € — € 99 € — € 99 Additions — 62 — 62 Disposals — (2) — (2) On December 31, 2018 — 159 — 159 Additions 39,881 262 — 40,143 On December 31, 2019 39,881 421 — 40,302 Additions 13,236 2,503 80,725 96,464 On December 31, 2020 € 53,117 € 2,924 € 80,725 € 136,766 Amortization and impairment On January 1, 2018 € — € (86) € — € (86) Amortization — (19) — (19) Disposals — 2 — 2 On December 31, 2018 — (103) — (103) Amortization — (38) — (38) On December 31, 2019 — (141) — (141) Amortization — (215) — (215) On December 31, 2020 € — € (356) € — € (356) Carrying Amount On December 31, 2018 € — € 56 € — € 56 On December 31, 2019 39,881 280 — 40,161 On December 31, 2020 € 53,117 € 2,568 € 80,725 € 136,410 |
Property, plant and equipment (
Property, plant and equipment (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Property, plant and equipment. | |
Schedule of property, plant and equipment | IT, office and lab Right-of-use assets Right-of-use assets Leasehold Lease (in thousands of €) equipment Buildings Vehicles improvements equipment (1) Total Cost On January 1, 2018 € 2,389 € — € — € — € — € 2,389 Additions 370 — — — 253 623 Disposals (47) — — — — (46) On December 31, 2018 2,712 — — — 253 2,965 Adoption of IFRS 16 — 2,338 452 — — 2,790 Additions 765 4,553 525 808 29 6,680 On December 31, 2019 3,477 6,891 977 808 282 12,435 Additions 597 2,718 875 352 — 4,542 Disposals (90) — — — — (90) On December 31, 2020 € 3,984 € 9,609 € 1,852 € 1,160 € 282 € 16,887 Depreciation and impairment On January 1, 2018 € (1,713) € — € — € — € — € (1,713) Depreciation (463) — — — (11) (474) Disposals 46 — — — — 46 On December 31, 2018 (2,130) — — — (11) (2,141) Depreciation (460) (1,315) (233) (92) (28) (2,128) On December 31, 2019 (2,590) (1,315) (233) (92) (39) (4,269) Depreciation (468) (1,981) (386) (351) (28) (3,214) Disposals 90 — — — — 90 On December 31, 2020 € (2,968) € (3,296) € (619) € (443) € (67) € (7,393) Carrying Amount On December 31, 2018 € 582 € — € — € — € 242 € 824 On December 31, 2019 887 5,576 744 716 243 8,167 On December 31, 2020 € 1,016 € 6,313 € 1,233 € 717 € 215 € 9,494 (1) The Company has elected not to reassess whether a contract is, or contains, a lease at the date of initial application. Instead, for contracts entered into before the transition date, the Company relied on its assessment made applying IAS 17 and IFRIC 4 Determining whether an Arrangement contains a Lease. |
Other non-current assets (Table
Other non-current assets (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Miscellaneous non-current assets [abstract] | |
Schedule of other non-current assets | Year Ended December 31, (in thousands of €) 2020 2019 2018 Restricted Cash - non-current € 1,243 € 630 € 251 Non-current financial assets held at fair value through profit or loss 5,140 2,596 1 Total other non-current assets € 6,383 € 3,226 € 252 |
Schedule of non current financial assets at fair value through profit or loss | Year Ended December 31, (in thousands of €) 2020 2019 2018 Cost at January 1 € 1,499 € — € — Acquisitions of the year — 1,499 — Cost at December 31 € 1,499 € 1,499 € — Fair value adjustments at January 1 € 1,097 € — € — Fair value adjustment of the year 2,544 1,097 — Fair value adjustment at December 31 € 3,641 € 1,097 € — Net book value at December 31 € 5,140 € 2,596 € — |
Deferred Taxes (Tables)
Deferred Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Deferred Taxes | |
Schedule of deferred tax assets and liability | The amount of deferred tax assets and liability by type of temporary difference can be detailed as follows: Year Ended December 31, 2020 (in thousands of €) Assets Liabilities Net Deferred tax assets / (liabilities) Accruals and allowances € 1,750 € — € 1,750 Income tax benefit from excess tax deductions related to share-based payments 10,889 — 10,889 Property, plant and equipment — (136) (136) Intangible assets — (1,460) (1,460) Netting by taxable entity (384) 384 — Net deferred tax assets / (liabilities) € 12,255 € (1,212) € 11,043 |
Schedule of change in net deferred taxes | The change in net deferred taxes recorded in the consolidated statement of financial position can be detailed as follows: (in thousands of €) Deferred tax assets Deferred tax liabilities Balance at January 1, 2020 € — € — Recognized in profit or loss 7,311 (1,212) Recognized in equity 5,073 — Effects of change in foreign exchange rate (129) — Balance at December 31, 2020 € 12,255 € (1,212) |
Inventories (Tables)
Inventories (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Inventories | |
Schedule of inventories | Year Ended December 31, (in thousands of €) 2020 2019 2018 Raw materials and consumables € 15,164 € — € — Inventories in process 5,368 — — Finished goods — — — Total inventories € 20,532 € — € — |
Trade and other receivables (Ta
Trade and other receivables (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Trade and other receivables | |
Schedule of trade and other receivables | Year Ended December 31, (in thousands of €) 2020 2019 2018 Trade receivable € 234 € 22,580 € 214 Interest receivable 809 2,081 556 Other receivable 4,644 3,454 2,116 € 5,687 € 28,115 € 2,886 |
Financial assets - current (Tab
Financial assets - current (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Financial assets - current | |
Schedule of current financial assets | Year Ended December 31, (in thousands of €) 2020 2019 2018 Money market funds € 106,177 € 715,773 € 283,529 Term accounts 529,182 288,766 — € 635,359 € 1,004,539 € 283,529 |
Cash and cash equivalents (Tabl
Cash and cash equivalents (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Cash and cash equivalents | |
Schedule of cash and cash equivalents | Year Ended December 31, (in thousands of €) 2020 2019 2018 Money market funds € 699,447 € — € — Term accounts 50,001 227,551 217,451 Cash and bank balances 242,161 103,731 63,589 € 991,609 € 331,282 € 281,040 |
Share capital and share premi_2
Share capital and share premium (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Share capital and share premium. | |
Schedule of number of share outstanding | Number of shares outstanding on January 1, 2018 32,180,641 Exercise of stock options 319,671 U.S. third public offering on Nasdaq on September 18, 2018 3,475,000 Number of shares outstanding on December 31, 2018 35,975,312 Exercise of stock options 419,317 Share subscription from Johnson & Johnson Innovation Inc. 1,766,899 Global public offering on Euronext and Nasdaq on November 7, 2019 4,000,000 Over-allotment option exercised by underwriters on November 8, 2019 600,000 Number of shares outstanding on December 31, 2019 42,761,528 Exercise of stock options 602,463 Global public offering in Euronext and Nasdaq on May 28, 2020 3,658,515 Over-allotment option exercised by underwriters on May 29, 2020 548,777 Number of shares outstanding on December 31, 2020 47,571,283 |
Share-based payments (Tables)
Share-based payments (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Share-based payments | |
Schedule of share based payment arrangement | Exercise price Outstanding per stock stock options on options December 31, Expiry date (in €) 2020 2019 2018 2020 € 3.95 — 7,210 18,200 2023 2.44 165,693 211,769 294,400 2024 2.44 100,086 102,696 144,703 2024 3.95 6,238 6,238 6,895 2024 7.17 294,167 335,067 407,061 2025 11.44 21,500 39,000 39,000 2025 10.34 950 3,000 3,000 2025 9.47 114,232 185,832 226,323 2026 11.38 45,000 45,000 50,415 2026 11.47 127,252 219,791 257,616 2026 14.13 176,426 258,746 315,102 2027 18.41 102,479 108,613 114,019 2027 21.17 460,701 565,798 628,292 2023 80.82 85,077 94,100 94,600 2028 80.82 49,532 73,100 75,450 2023 86.32 325,661 366,260 369,760 2028 86.32 381,317 402,714 491,815 2024 113.49 111,174 111,690 — 2029 113.49 163,410 299,560 — 2024 135.75 195,452 204,430 — 2029 135.75 692,914 717,455 — 2025 119.53 19,000 — — 2030 119.53 123,700 — — 2025 196.15 131,770 — — 2030 196.15 325,150 — — 2025 200.22 32,100 — — 2030 200.22 175,200 — — 2030 247.60 31,200 — — 2025/2030 (1) € 247.60 908,362 — — 5,365,743 4,358,069 3,536,651 (1) In December 2020, the Company granted options for which the beneficiaries had a 60-day period to choose between a contractual term of five or ten years. |
Schedule of number of stock options | 2020 2019 2018 Number of Weighted average Number of Weighted average Number of Weighted average stock options exercise price stock options exercise price stock options exercise price Outstanding at January 1 4,358,069 € 63.75 3,536,651 € 33.42 2,862,216 € 11.54 Granted 1,797,652 217.35 1,365,172 128.52 1,040,475 85.37 Exercised (602,463) 31.67 (419,317) 11.35 (319,671) 7.02 Forfeited (187,515) 139.34 (124,437) 88.92 (46,369) 30.44 Outstanding at December 31 5,365,743 116.43 4,358,069 63.75 3,536,651 33.42 Exercisable at December 31 2,833,680 € 53.17 2,203,476 € 22.59 1,859,315 € 9.62 |
Schedule of weighted average remaining contractual life for each range of exercise price: | Weighted average remaining Outstanding on contractual life Exercise price (in €) December 31, 2020 (in years) 2.44 - 3.95 272,017 3.08 7.17 - 9.47 408,399 4.24 10.34 - 14.13 371,128 5.62 18.41 - 21.17 563,180 6.87 80.82 - 86.32 841,587 5.46 113.49 - 135.75 1,305,650 7.64 196.15 - 247.60 1,603,782 9.29 |
Schedule of parameters used in relation to the new grants | Below is an overview of the parameters used in relation to the determination of the fair value of the grants during 2020: Stock options granted in April 2020 June 2020 Oct 2020 Dec 2020 Number of options granted 142,700 550,090 196,500 908,362 Fair value of options (in EUR) € 62.31 - 120.63 € 68.01 - 105.65 € 74.24 - 127.68 € 119.26 - 124.67 Share price (in EUR) € 126.50 - 205.60 € 183.20 - 229.20 € 209.00 - 239.20 € 247.4 Exercise price (in EUR) € 119.53 € 196.15 € 200.22 € 247.6 Expected volatility 44.44 - 64.77 % 43.46 - 52.19 % 44.17 - 52.71 % 53.00 - 53.51 % Expected option life (in years) 4 - 6.68 4 - 6.68 4 - 6.68 6.15 - 6.68 (1) Risk‑free interest rate (0.32) - (0.18) % (0.43) - (0.28) % (0.51) - (0.34) % (0.42) - (0.40) % Expected dividends — % — % — % — % (1) In December 2020, the Company granted a total of 908,362 stock options. The beneficiary can choose between a contractual term of five or ten years. The expected option life ranges between 6.15 and 6.68 years. This estimate will be reassessed once the acceptance period of 60 days has passed and the beneficiaries will have made a choice between a contractual term of five or ten years. The total fair value of the grant would range from €84.5 million (100% of the stock options with a contractual term of five years) to €110.3 million (100% of the stock options with a conctractual term of ten years ). Below is an overview of the parameters used in relation to the determination of the fair value of grants during 2019: Stock options granted in June 2019 Nov 2019 Dec 2019 Number of options granted 423,487 19,800 921,885 Average Fair value of options (in EUR) € 63.45 € 57.69 € 41.40 - 66.39 Share price (in EUR) € 123.20 € 126.40 € 130.1 - 150.7 Exercise price (in EUR) € 113.49 € 113.49 € 135.75 Expected volatility 45.25 % 44.14 43.80 - 44.11 % Average Expected option life (in years) 8.59 6.50 4 - 6.5 Risk‑free interest rate 0.07 % (0.05) (0.57) - (0.24) % Expected dividends — % — — % Below is an overview of the parameter used in relation to the determination of the fair value of grants during 2018: Stock options granted in June 2018 Dec 2018 Number of options granted 178,900 861,575 Fair value of options (in EUR) € 32.12 € 39.85 Share price (in EUR) € 72.00 € 82.20 Exercise price (in EUR) € 80.82 € 86.32 Expected volatility 45.50 % 46.19 % Average expected option life (in years) 7.36 7.83 Risk‑free interest rate 0.72 % 0.77 % Expected dividends — % — % |
Trade and other payables (Table
Trade and other payables (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Trade and other payables | |
Schedule of trade and other payables | Year Ended December 31, (in thousands of €) 2020 2019 2018 Trade payables € 168,140 € 58,429 € 24,152 Short‑term employee benefits 56,122 26,872 12,920 € 224,262 € 85,301 € 37,072 |
Revenue (Tables)
Revenue (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Revenue | |
Schedule of revenue | Year Ended December 31, (in thousands of €) 2020 2019 2018 Upfront payments € 30,348 € 22,360 € 8,635 Janssen 29,818 20,056 — AbbVie 497 761 8,455 Agomab — 1,499 — Other 33 44 180 Milestone payments 3,021 28,085 11,440 Janssen 2,333 1,569 — AbbVie 671 26,494 10,510 Other 17 22 930 Research and development service fees 3,056 19,338 1,407 Janssen 2,807 18,968 — Other 249 370 1,407 Total revenue € 36,425 € 69,783 € 21,482 |
Summarizes of changes in deferred revenue current and deferred revenue non current | (in thousands of €) Janssen AbbVie Other Total On January 1, 2018 € — € 12,376 € 344 € 12,720 Received Milestone — 8,633 883 9,516 Revenue recognition Upfront — (8,455) (180) (8,635) Milestone — (10,510) (930) (11,440) On December 31, 2018 — 2,045 116 2,161 Received Upfront 288,060 288,060 Milestone 22,535 26,560 49,095 Revenue recognition Upfront (20,056) (761) (44) (20,861) Milestone (1,569) (26,494) (22) (28,085) On December 31, 2019 288,971 1,350 50 290,371 Received Milestone — — — — Revenue recognition Upfront (29,818) (497) (33) (30,348) Milestone (2,333) (671) (17) (3,021) On December 31, 2020 € 256,819 € 182 € (0) € 257,001 |
Other operating income (Tables)
Other operating income (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Other operating income | |
Schedule of other operating income | Year Ended December 31, (in thousands of €) 2020 2019 2018 Grants € 1,226 € 2,289 € 1,842 Research and development incentives 8,875 4,818 2,151 Payroll tax rebates 8,008 5,694 3,756 € 18,109 € 12,801 € 7,749 |
Segment reporting (Tables)
Segment reporting (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Segment reporting | |
Schedule of external customers geographically location | Revenue from external customers Year ended December 31, (in thousands of €) 2020 2019 2018 Denmark € 299 € 436 € 1,136 Belgium — 1,499 — United States 36,126 67,848 18,964 Other — — 1,382 Total € 36,425 € 69,783 € 21,482 Non-current assets Year ended December 31, (in thousands of €) 2020 2019 2018 Netherlands € 1 € 1 € 1 Belgium 163,224 56,777 5,967 United States 3,872 3,058 47 Japan 2,030 284 — Total € 169,127 € 60,120 € 6,015 |
Research and development expe_2
Research and development expenses (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Research and development expenses | |
Schedule of research and development expenses | Year Ended December 31, (in thousands of €) 2020 2019 2018 Personnel expense € 75,121 € 45,733 € 26,519 External research and development expenses 228,438 137,050 48,859 Materials and consumables 3,099 2,027 1,464 Depreciation and amortization 2,472 1,641 494 Other expenses 16,349 11,214 6,273 € 325,479 € 197,665 € 83,609 |
Selling, general and administ_2
Selling, general and administrative expenses (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Selling, general and administrative expenses | |
Schedule of selling, general and administrative expenses | Year Ended December 31, (in thousands of €) 2020 2019 2018 Personnel expense € 94,251 € 40,082 € 18,292 Consulting fees 42,459 16,343 5,472 Supervisory board 4,243 2,792 1,088 Other Expenses 8,414 5,352 2,619 € 149,367 € 64,569 € 27,471 |
Personnel expenses (Tables)
Personnel expenses (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Personnel expenses | |
Schedule of personnel expenses | Year Ended December 31, (in thousands of €) 2020 2019 2018 Short‑term employee benefits—Salaries € 65,516 € 32,866 € 18,617 Short‑term employee benefits—Social Security 7,848 3,555 2,213 Post‑employment benefits 1,072 748 441 Termination benefits 849 644 96 Share‑based payment 80,644 37,208 18,527 Employer social security contributions stock options 13,443 10,794 4,918 € 169,372 € 85,815 € 44,812 |
Schedule of full-time equivalents employees | Year Ended December 31, Average Number of FTE 2020 2019 2018 Research and development 213.0 121.6 76.1 Selling, general and administrative 119.5 56.3 27.6 332.5 177.9 103.7 |
Leases (Tables)
Leases (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Leases | |
Schedule of financial position relating to leases | Year Ended December 31, December 31, In thousands of € 2020 2019 Right-of-use assets Buildings € 6,313 € 5,576 Vehicles 1,233 744 Equipment 215 243 € 7,760 € 6,563 Lease liabilities Current € 2,833 € 1,974 Non-current 5,035 4,540 € 7,868 € 6,514 |
Schedule of maturity analysis of the lease liabilities | (in thousands of €) Less than 1 year 1-3 years 3-5 years More than 5 years Total contractual cash flows Carrying amount Lease liabilities € 3,043 € 4,085 € 1,171 € — € 8,299 € 7,868 |
Schedule of total lease liabilities recognized in our statement of financial position | Year Ended December 31, In thousands of € 2020 2019 2018 Depreciation charges Buildings € 1,981 € 1,315 € — Vehicles 386 233 — Equipment 28 28 11 € 2,395 € 1,576 € 11 Interest expense (included in finance cost) € 176 € 105 € — Expense relating to short-term leases 231 123 — Expense relating to leases of low-value assets that are not shown above as short-term leases 5 5 — |
Financial result and exchange_2
Financial result and exchange gains/(losses) (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Financial result and exchange gains/(losses) | |
Schedule of financial result and exchange gains/(losses) | Year Ended December 31, (in thousands of €) 2020 2019 2018 Interest income € 4,517 € 7,874 € 1,371 Net gain on current financial assets held at fair value through profit or loss and cash equivalents 1,173 6,525 2,323 Financial income € 5,690 € 14,399 € 3,694 Net loss on current financial assets held at fair value through profit or loss and cash equivalents € (6,755) € — € Other financial expense (349) (124) — Financial expense € (7,104) € (124) € — Realized exchange gains/(losses) € (400) € (338) € 1,355 Unrealized exchange gains/(losses) (106,556) 6,404 10,953 Exchange gains/(losses) € (106,956) € 6,066 € 12,308 |
Income tax expense (Tables)
Income tax expense (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Income tax expense | |
Schedule of income tax expenses | Year Ended December 31, (in thousands of €) 2020 2019 2018 Loss before taxes € 526,139 € 158,213 € 65,847 Income tax calculated at 25% 131,535 39,553 16,462 Effect of expenses not deductible in determining taxable results (11,478) (7,701) (3,934) Effect of stock issue expenses that are not deductible in determining taxable results 11,775 5,750 3,716 Effect of concessions 6,804 572 430 Effect of tax losses carried forward not recognized (100,771) (11,670) (5,511) Effect of different tax rates in jurisdictions in which the company operates (168) (52) (15) Deferred tax asset other than loss carryforwards not recognized (39,516) (27,341) (11,968) (Underprovided)/overprovided in prior years (857) (3,876) Other (108) 13 26 Income tax expense recognized in the consolidated statement of profit and loss € (2,784) € (4,752) € (794) |
Schedule of income taxes recognized in income | Year Ended December 31, (in thousands of €) 2020 2019 2018 Current year € 6,871 € 4,752 794 Income tax prior years 1,547 — — Current tax expense 8,418 4,752 794 Originating and reversal of temporary differences (5,634) — — Deferred tax expense / (income) (5,634) — — Total tax expense € 2,784 € 4,752 € 794 |
Loss per share (Tables)
Loss per share (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Loss per share | |
Schedule of loss per share | Year Ended December 31, (in thousands of €) 2020 2019 2018 Loss of the year € (528,923) € (162,965) € (66,641) Weighted average number of shares outstanding 45,410,442 38,619,121 33,419,356 Basic and diluted loss per share (in €) € (11.65) € (4.22) € (1.99) |
Financial risk management (Tabl
Financial risk management (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Financial risk management | |
Schedule of overview of financial instruments | Measurement category Carrying amount Year Ended December 31, (in thousands of €) 2020 2019 2018 Financial assets — non-current FVTPL € 5,140 € 2,596 € 1 Research and development incentive receivables — non-current Amortised cost 16,840 8,566 4,883 Restricted cash — non-current Amortised cost 1,243 630 251 Trade and other receivables Amortised cost 5,687 28,115 2,886 Financial assets—current FVTPL 635,359 1,004,539 283,529 Research and development incentive receivables — current Amortised cost 377 261 301 Restricted cash — current Amortised cost — — 1,692 Cash and bank balances Amortised cost 242,161 103,731 63,589 Cash equivalents FVTPL 699,447 — — Cash equivalents Amortised cost 50,001 227,551 217,451 Trade and other payables Amortised cost 224,262 85,301 37,072 |
Schedule of assets at fair value | At December 31, 2020 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 5,140 Current financial assets 635,359 — — Cash Equivalents 699,447 — — Assets carried at fair value € 1,334,806 € — € 5,140 At December 31, 2019 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 2,596 Current financial assets 1,004,539 — — Assets carried at fair value € 1,004,539 € — € 2,596 At December 31, 2018 (in thousands of €) Level 1 Level 2 Level 3 Non-current financial assets € — € — € 1 Current financial assets 283,529 — — Assets carried at fair value € 283,529 € — € 1 |
Schedule of net exposure exchange differences of the monetary assets | At December 31, (in thousands of €) 2020 2019 2018 USD 1,053,803 821,916 312,831 JPY 215 488 — GBP 39 4 2 CHF 94 1 4 |
Related party transactions (Tab
Related party transactions (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Related party transactions | |
Schedule of remuneration of key management personnel | Year Ended December 31, (in thousands of €, except for the number of stock options) 2020 2019 2018 Remuneration of key management personnel Short-term benefits for executive team members as a group Gross salary € 2,842 € 2,527 € 2,505 Variable pay 1,322 975 1,078 Employer social security 659 813 528 Other short term benefits 137 122 125 Termination Benefits 337 470 — Post-employment benefits for executive team members as a group 141 144 153 Cost of stock options granted in the year for executive team members as a group 37,493 21,847 13,363 Employer social security cost related to stock options 9,811 9,160 2,793 Total benefits for key management personnel 52,742 36,058 20,544 Numbers of stock options granted in the year Executive team as a group Remuneration of non-executive directors Board fees and other short-term benefits for directors 355 378 355 Cost of stock options granted in the year for non-executive directors 8,384 4,330 3,271 Total benefits for non-executive board members 8,739 4,708 3,626 Numbers of stock options granted in the year Non-executive directors 70,000 — 70,000 85,000 |
Commitments (Tables)
Commitments (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Commitments | |
Schedule of future cash outflows | (in thousands of €) Less than 1 year 1-3 years 3-5 years More than 5 years Total contractual cash flows Lease commitments not commenced € — € 282 € 3,382 € 13,247 € 16,912 |
Audit fees (Tables)
Audit fees (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Audit fees | |
Schedule of auditors' fees expensed in the income statement | The following auditors’ fees were expensed in the income statement: Year Ended December 31, Fees 2020 2019 2018 in thousands of € Audit fees (1) € 808 € 730 € 648 Audit-related fees 165 159 143 Tax and other services (2) — — — Total € 973 € 889 € 791 (1) Audit services performed by Deloitte Accountants B.V. as the external auditor referred to in Section 1 of the Dutch Accounting Firms Oversight Act (Wta) as well as by the Deloitte network. (2) Tax and other services performed by the Deloitte network. |
Overview of consolidation sco_2
Overview of consolidation scope (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Overview of consolidation scope | |
Schedule of overview of subsidiaries | Name Registration number Country Participation Main activity argenx SE COC 24435214 The Netherlands 100.00 % Holding company argenx BV Belgium 100.00 % Biotechnical research on drugs and pharma processes argenx IIP BV Belgium 100.00 % Biotechnical research on drugs and pharma processes argenx US, Inc. 36-4880497 USA 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers argenx Switzerland, SA CH-660.3.799.020-7 Switzerland 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers argenx Japan KK 0104-01-145183 Japan 100.00 % Pharmaceuticals and pharmacy supplies merchant wholesalers |
Significant accounting polici_4
Significant accounting policies - Intangible Assets (Details) - Software & databases | 12 Months Ended |
Dec. 31, 2020 | |
Minimum | |
Intangible assets | |
Estimated useful life | 3 years |
Maximum | |
Intangible assets | |
Estimated useful life | 5 years |
Significant accounting polici_5
Significant accounting policies - Property, plant and equipment and Others (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2020EUR (€)item | |
Property, plant and equipment | |
Impairment of assets | € 0 |
Profit available for distribution | € 0 |
Number of operating segments | item | 1 |
IT equipment | |
Property, plant and equipment | |
Estimated useful life | 3 years |
Minimum | Office and lab equipment | |
Property, plant and equipment | |
Estimated useful life | 3 years |
Maximum | Office and lab equipment | |
Property, plant and equipment | |
Estimated useful life | 5 years |
Significant accounting polici_6
Significant accounting policies - New accounting policies and disclosures (Details) - EUR (€) € in Thousands | Jan. 01, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of expected impact of initial application of new standards or interpretations [line items] | ||||
Operating lease commitments | € 3,004 | |||
Less: discounting effect using the lessee's incremental borrowing rate of the date of initial application | € (126) | |||
Less: short-term leases recognized on a straight-line basis as expense | (88) | € (231) | € (123) | |
Lease liabilities | 2,790 | 7,868 | 6,514 | |
Current lease liabilities | 1,078 | 2,833 | 1,974 | |
Non-current lease liabilities | € 1,712 | € 5,035 | € 4,540 | |
IFRS 16 | ||||
Disclosure of expected impact of initial application of new standards or interpretations [line items] | ||||
Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16 | 1.32% |
Significant accounting polici_7
Significant accounting policies - Cumulative effect of adopting IFRS 16 (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Disclosure of initial application of standards or interpretations [line items] | ||||
Property, plant and equipment (right-of-use assets) | € 7,760 | € 6,563 | ||
Lease liabilities (current and non-current) | 7,868 | 6,514 | € 2,790 | |
Effect on total equity and liabilities | € 1,857,695 | € 1,433,339 | € 578,458 | |
Increase (decrease) due to application of IFRS 16 | ||||
Disclosure of initial application of standards or interpretations [line items] | ||||
Property, plant and equipment (right-of-use assets) | 2,790 | |||
Effect on total assets | 2,790 | |||
Lease liabilities (current and non-current) | 2,790 | |||
Effect on total equity and liabilities | € 2,790 |
Critical accounting judgement_2
Critical accounting judgements and key sources of estimation uncertainty - (Details) € in Millions | Dec. 31, 2020EUR (€) |
Clinical Manufacturing Organizations | |
Research and development cost accruals | |
Research and development cost accruals | € 52.6 |
Intangible assets (Details)
Intangible assets (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | € 40,161 | € 56 | |
Intangible assets other than goodwill at end of period | 136,410 | 40,161 | € 56 |
Commitments to acquire additional intangible assets | 0 | ||
Intangible assets are pledged as security | 0 | ||
Acquired In-Process R&D | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | 39,881 | ||
Intangible assets other than goodwill at end of period | 53,117 | 39,881 | |
Software & databases | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | 280 | 56 | |
Intangible assets other than goodwill at end of period | 2,568 | 280 | 56 |
Other Intangibles | |||
Intangible assets | |||
Intangible assets other than goodwill at end of period | 80,725 | ||
Cost | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | 40,302 | 159 | 99 |
Additions | 96,464 | 40,143 | 62 |
Disposals | (2) | ||
Intangible assets other than goodwill at end of period | 136,766 | 40,302 | 159 |
Cost | Acquired In-Process R&D | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | 39,881 | ||
Additions | 13,236 | 39,881 | |
Intangible assets other than goodwill at end of period | 53,117 | 39,881 | |
Cost | Software & databases | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | 421 | 159 | 99 |
Additions | 2,503 | 262 | 62 |
Disposals | (2) | ||
Intangible assets other than goodwill at end of period | 2,924 | 421 | 159 |
Cost | Other Intangibles | |||
Intangible assets | |||
Additions | 80,725 | ||
Intangible assets other than goodwill at end of period | 80,725 | ||
Accumulated depreciation and amortization | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | (141) | (103) | (86) |
Amortization | (215) | (38) | (19) |
Disposals | 2 | ||
Intangible assets other than goodwill at end of period | (356) | (141) | (103) |
Accumulated depreciation and amortization | Software & databases | |||
Intangible assets | |||
Intangible assets other than goodwill at beginning of period | (141) | (103) | (86) |
Amortization | (215) | (38) | (19) |
Disposals | 2 | ||
Intangible assets other than goodwill at end of period | € (356) | € (141) | € (103) |
Property, plant and equipment_2
Property, plant and equipment (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | € 8,167 | € 824 | |
Property, plant and equipment at end of period | 9,494 | 8,167 | € 824 |
Commitments to acquire property, plant and equipment | 0 | ||
Assets are pledged as security for liabilities | 0 | ||
Office and lab equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 887 | 582 | |
Property, plant and equipment at end of period | 1,016 | 887 | 582 |
Buildings | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 5,576 | ||
Property, plant and equipment at end of period | 6,313 | 5,576 | |
Vehicles | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 744 | ||
Property, plant and equipment at end of period | 1,233 | 744 | |
Leasehold improvements | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 716 | ||
Property, plant and equipment at end of period | 717 | 716 | |
Lease equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 243 | 242 | |
Property, plant and equipment at end of period | 215 | 243 | 242 |
Cost | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 2,965 | 2,389 | |
Additions | 6,680 | 623 | |
Disposals | (46) | ||
Property, plant and equipment at end of period | 2,965 | ||
Cost | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 12,435 | 2,790 | |
Additions | 4,542 | ||
Disposals | (90) | ||
Property, plant and equipment at end of period | 16,887 | 12,435 | 2,790 |
Cost | Office and lab equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 2,712 | 2,389 | |
Additions | 765 | 370 | |
Disposals | (47) | ||
Property, plant and equipment at end of period | 2,712 | ||
Cost | Office and lab equipment | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 3,477 | ||
Additions | 597 | ||
Disposals | (90) | ||
Property, plant and equipment at end of period | 3,984 | 3,477 | |
Cost | Buildings | |||
Property, plant and equipment | |||
Additions | 4,553 | ||
Cost | Buildings | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 6,891 | 2,338 | |
Additions | 2,718 | ||
Property, plant and equipment at end of period | 9,609 | 6,891 | 2,338 |
Cost | Vehicles | |||
Property, plant and equipment | |||
Additions | 525 | ||
Cost | Vehicles | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 977 | 452 | |
Additions | 875 | ||
Property, plant and equipment at end of period | 1,852 | 977 | 452 |
Cost | Leasehold improvements | |||
Property, plant and equipment | |||
Additions | 808 | ||
Cost | Leasehold improvements | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 808 | ||
Additions | 352 | ||
Property, plant and equipment at end of period | 1,160 | 808 | |
Cost | Lease equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 253 | ||
Additions | 29 | 253 | |
Property, plant and equipment at end of period | 253 | ||
Cost | Lease equipment | IFRS 16 | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | 282 | ||
Property, plant and equipment at end of period | 282 | 282 | |
Accumulated depreciation and amortization | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (4,269) | (2,141) | (1,713) |
Depreciation | (3,214) | (2,128) | (474) |
Disposals | 90 | 46 | |
Property, plant and equipment at end of period | (7,393) | (4,269) | (2,141) |
Accumulated depreciation and amortization | Office and lab equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (2,590) | (2,130) | (1,713) |
Depreciation | (468) | (460) | (463) |
Disposals | 90 | 46 | |
Property, plant and equipment at end of period | (2,968) | (2,590) | (2,130) |
Accumulated depreciation and amortization | Buildings | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (1,315) | ||
Depreciation | (1,981) | (1,315) | |
Property, plant and equipment at end of period | (3,296) | (1,315) | |
Accumulated depreciation and amortization | Vehicles | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (233) | ||
Depreciation | (386) | (233) | |
Property, plant and equipment at end of period | (619) | (233) | |
Accumulated depreciation and amortization | Leasehold improvements | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (92) | ||
Depreciation | (351) | (92) | |
Property, plant and equipment at end of period | (443) | (92) | |
Accumulated depreciation and amortization | Lease equipment | |||
Property, plant and equipment | |||
Property, plant and equipment at beginning of period | (39) | (11) | |
Depreciation | (28) | (28) | (11) |
Property, plant and equipment at end of period | € (67) | € (39) | € (11) |
Other non-current assets - (Det
Other non-current assets - (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Miscellaneous non-current assets [abstract] | ||||
Restricted cash — non-current | € 1,243 | € 630 | € 251 | |
Non-current financial assets held at fair value through profit or loss | 5,140 | 2,596 | 1 | |
Total other non-current assets | 6,383 | 3,226 | € 252 | |
Secured Series A Financing | € 1,499 | € 1,499 | € 21,000 |
Other non-current assets - Fair
Other non-current assets - Fair Value (Details) - EUR (€) € in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Miscellaneous non-current assets [abstract] | ||
Cost at beginning | € 1,499 | |
Acquisitions of the year | € 1,499 | |
Cost at ending | 1,499 | 1,499 |
Fair value adjustments at beginning | 1,097 | |
Fair value adjustment of the year | 2,544 | 1,097 |
Fair value adjustments at ending | 3,641 | 1,097 |
Net book value at ending | € 5,140 | € 2,596 |
Deferred Taxes - Deferred tax a
Deferred Taxes - Deferred tax assets and liability (Details) € in Thousands | Dec. 31, 2020EUR (€) |
Deferred tax assets / (liabilities) | |
Accruals and allowances | € 1,750 |
Property, plant and equipment | 136 |
Intangible assets | 1,460 |
Netting by taxable entity | (384) |
Netting by taxable entity | (384) |
Deferred tax assets | 12,255 |
Deferred tax liabilities | 1,212 |
Net deferred tax assets / (liabilities) | 11,043 |
Income tax benefit from excess tax deductions related to share-based payments | |
Deferred tax assets / (liabilities) | |
Deferred tax assets | 10,889 |
Net deferred tax assets / (liabilities) | € 10,889 |
Deferred Taxes - (Details)
Deferred Taxes - (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2020EUR (€) | |
Deferred Tax Asset | |
Recognized in profit or loss | € 7,311 |
Recognized in equity | 5,073 |
Effects of change in foreign exchange rate | (129) |
Balance at end of period | 12,255 |
Reconciliation of Changes In Deferred Tax Liability [Abstract] | |
Recognized in profit or loss | (1,212) |
Balance at end of period | € 1,212 |
Inventories (Details)
Inventories (Details) € in Thousands | 12 Months Ended |
Dec. 31, 2020EUR (€) | |
Inventories | |
Raw materials and consumables | € 15,164 |
Inventories in process | 5,368 |
Total inventories | 20,532 |
Inventory write down | € 0 |
Trade and other receivables (De
Trade and other receivables (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Trade and other receivables | |||
Trade receivables | € 234 | € 22,580 | € 214 |
Interest receivable | 809 | 2,081 | 556 |
Other receivables | 4,644 | 3,454 | 2,116 |
Total trade and other current receivables | € 5,687 | € 28,115 | € 2,886 |
Financial assets - current (Det
Financial assets - current (Details) € in Thousands, $ in Millions | 12 Months Ended | |||
Dec. 31, 2020EUR (€) | Dec. 31, 2020USD ($) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | |
Other current financial assets | ||||
Financial assets — current | € 635,359 | $ 717.1 | € 1,004,539 | € 283,529 |
Money market funds | ||||
Other current financial assets | ||||
Financial assets — current | 106,177 | 715,773 | € 283,529 | |
Term accounts | ||||
Other current financial assets | ||||
Financial assets — current | € 529,182 | € 288,766 | ||
Minimum | ||||
Other current financial assets | ||||
Maturity Term | 3 months | |||
Maximum | ||||
Other current financial assets | ||||
Maturity Term | 12 months |
Cash and cash equivalents (Deta
Cash and cash equivalents (Details) € in Thousands, $ in Millions | Dec. 31, 2020EUR (€) | Dec. 31, 2020USD ($) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) |
Cash and cash equivalents | |||||
Money market funds | € 699,447 | ||||
Term Accounts | 50,001 | € 227,551 | € 217,451 | ||
Cash and bank balances | 242,161 | 103,731 | 63,589 | ||
Total cash and cash equivalents | 991,609 | $ 576.1 | 331,282 | 281,040 | € 190,867 |
Cash and cash equivalents. | € 991,609 | $ 576.1 | € 331,282 | € 281,040 | € 190,867 |
Share capital and share premi_3
Share capital and share premium (Details) - EUR (€) | May 29, 2020 | May 28, 2020 | May 12, 2020 | Nov. 08, 2019 | Nov. 07, 2019 | Sep. 18, 2018 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of classes of share capital [line items] | |||||||||
Number of shares outstanding | 47,571,283 | 42,761,528 | 35,975,312 | ||||||
Number of shares outstanding at beginning of period | 42,761,528 | 35,975,312 | 32,180,641 | ||||||
New shares issued for private placement, initial public offering, public offering and underwriters' over-allotment option | 548,777 | 3,658,515 | 600,000 | 4,000,000 | 3,475,000 | ||||
Exercise of Options | 602,463 | 419,317 | 319,671 | ||||||
Number of shares outstanding at end of period | 47,571,283 | 42,761,528 | 35,975,312 | ||||||
Number of shares on conversion | 1 | ||||||||
Maximum authorized increase of then outstanding share capital (as a percent) | 10.00% | ||||||||
Period of outstanding share capital | 18 months | ||||||||
Maximum authorized increase in share capital | € 427,974.7 | ||||||||
Maximum authorized increase in number of shares | 4,279,747 | ||||||||
Johnson & Johnson Innovation Inc | |||||||||
Disclosure of classes of share capital [line items] | |||||||||
Share subscription from Johnson & Johnson Innovation Inc. | 1,766,899 |
Share-based payments (Details)
Share-based payments (Details) | Nov. 25, 2020 | Dec. 31, 2020EquityInstrumentsY€ / shares | Oct. 31, 2020EquityInstrumentsY€ / shares | Jun. 30, 2020EquityInstrumentsY€ / shares | Apr. 30, 2020EquityInstrumentsY€ / shares | Dec. 31, 2019EquityInstrumentsY€ / shares | Nov. 30, 2019EquityInstrumentsY€ / shares | Jun. 30, 2019EquityInstrumentsY€ / shares | Dec. 31, 2018EquityInstrumentsY€ / shares | Jun. 30, 2018EquityInstrumentsY€ / shares | Dec. 31, 2020EquityInstrumentsY€ / sharesshares | Dec. 31, 2019EquityInstruments€ / shares | Dec. 31, 2018EquityInstruments€ / shares | Dec. 31, 2017EquityInstruments |
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Number of shares on conversion | shares | 1 | |||||||||||||
Number of options granted | 908,362 | 196,500 | 550,090 | 142,700 | 921,885 | 19,800 | 423,487 | 861,575 | 178,900 | 1,797,652 | 1,365,172 | 1,040,475 | ||
Vesting period | 36 months | 24 months | ||||||||||||
Exercise price per stock options | € / shares | € 247.6 | € 200.22 | € 196.15 | € 119.53 | € 135.75 | € 113.49 | € 113.49 | € 86.32 | € 80.82 | € 247.6 | € 135.75 | € 86.32 | ||
Outstanding stock options | 5,365,743 | 4,358,069 | 3,536,651 | 5,365,743 | 4,358,069 | 3,536,651 | 2,862,216 | |||||||
Time period for beneficiaries to choose contractual term | 60 days | |||||||||||||
Option life (in years) | Y | 6.50 | 8.59 | 7.83 | 7.36 | ||||||||||
Number of share options granted being used to pay tax by transferring the economic benefits | shares | 126,982 | |||||||||||||
Tranche One | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting percentage | 25.00% | 33.00% | ||||||||||||
Tranche Two | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Vesting percentage | 2.80% | 4.16% | ||||||||||||
Percentage of stock options granted | 67.00% | 75.00% | ||||||||||||
3.95 | 2020 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 3.95 | € 3.95 | ||||||||||||
Outstanding stock options | 7,210 | 18,200 | 7,210 | 18,200 | ||||||||||
3.95 | 2024 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 3.95 | € 3.95 | ||||||||||||
Outstanding stock options | 6,238 | 6,238 | 6,895 | 6,238 | 6,238 | 6,895 | ||||||||
2.44 - Expiry date 2024 option 1 | 2023 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 2.44 | € 2.44 | ||||||||||||
Outstanding stock options | 165,693 | 211,769 | 294,400 | 165,693 | 211,769 | 294,400 | ||||||||
2.44 - Expiry date 2024 option 2 | 2024 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 2.44 | € 2.44 | ||||||||||||
Outstanding stock options | 100,086 | 102,696 | 144,703 | 100,086 | 102,696 | 144,703 | ||||||||
7.17 | 2024 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 7.17 | € 7.17 | ||||||||||||
Outstanding stock options | 294,167 | 335,067 | 407,061 | 294,167 | 335,067 | 407,061 | ||||||||
11.44 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 11.44 | € 11.44 | ||||||||||||
Outstanding stock options | 21,500 | 39,000 | 39,000 | 21,500 | 39,000 | 39,000 | ||||||||
10.34 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 10.34 | € 10.34 | ||||||||||||
Outstanding stock options | 950 | 3,000 | 3,000 | 950 | 3,000 | 3,000 | ||||||||
9.47 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 9.47 | € 9.47 | ||||||||||||
Outstanding stock options | 114,232 | 185,832 | 226,323 | 114,232 | 185,832 | 226,323 | ||||||||
11.38 | 2026 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 11.38 | € 11.38 | ||||||||||||
Outstanding stock options | 45,000 | 45,000 | 50,415 | 45,000 | 45,000 | 50,415 | ||||||||
135.75 | 2024 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 135.75 | € 135.75 | ||||||||||||
Outstanding stock options | 195,452 | 204,430 | 195,452 | 204,430 | ||||||||||
135.75 | 2029 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 135.75 | € 135.75 | ||||||||||||
Outstanding stock options | 692,914 | 717,455 | 692,914 | 717,455 | ||||||||||
11.47 | 2026 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 11.47 | € 11.47 | ||||||||||||
Outstanding stock options | 127,252 | 219,791 | 257,616 | 127,252 | 219,791 | 257,616 | ||||||||
14.13 | 2026 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 14.13 | € 14.13 | ||||||||||||
Outstanding stock options | 176,426 | 258,746 | 315,102 | 176,426 | 258,746 | 315,102 | ||||||||
18.41 | 2027 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 18.41 | € 18.41 | ||||||||||||
Outstanding stock options | 102,479 | 108,613 | 114,019 | 102,479 | 108,613 | 114,019 | ||||||||
21.17 | 2027 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 21.17 | € 21.17 | ||||||||||||
Outstanding stock options | 460,701 | 565,798 | 628,292 | 460,701 | 565,798 | 628,292 | ||||||||
80.82 | 2023 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 80.82 | € 80.82 | ||||||||||||
Outstanding stock options | 85,077 | 94,100 | 94,600 | 85,077 | 94,100 | 94,600 | ||||||||
80.82 | 2028 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 80.82 | € 80.82 | ||||||||||||
Outstanding stock options | 49,532 | 73,100 | 75,450 | 49,532 | 73,100 | 75,450 | ||||||||
86.32 | 2023 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 86.32 | € 86.32 | ||||||||||||
Outstanding stock options | 325,661 | 366,260 | 369,760 | 325,661 | 366,260 | 369,760 | ||||||||
86.32 | 2028 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 86.32 | € 86.32 | ||||||||||||
Outstanding stock options | 381,317 | 402,714 | 491,815 | 381,317 | 402,714 | 491,815 | ||||||||
113.49 | 2024 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 113.49 | € 113.49 | ||||||||||||
Outstanding stock options | 111,174 | 111,690 | 111,174 | 111,690 | ||||||||||
113.49 | 2029 | Tranche One | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 113.49 | € 113.49 | ||||||||||||
Outstanding stock options | 163,410 | 299,560 | 163,410 | 299,560 | ||||||||||
119.53 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 119.53 | € 119.53 | ||||||||||||
Outstanding stock options | 19,000 | 19,000 | ||||||||||||
119.53 | 2030 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 119.53 | € 119.53 | ||||||||||||
Outstanding stock options | 123,700 | 123,700 | ||||||||||||
196.15 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 196.15 | € 196.15 | ||||||||||||
Outstanding stock options | 131,770 | 131,770 | ||||||||||||
196.15 | 2030 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 196.15 | € 196.15 | ||||||||||||
Outstanding stock options | 325,150 | 325,150 | ||||||||||||
200.22 | 2025 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 200.22 | € 200.22 | ||||||||||||
Outstanding stock options | 32,100 | 32,100 | ||||||||||||
200.22 | 2030 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 200.22 | € 200.22 | ||||||||||||
Outstanding stock options | 175,200 | 175,200 | ||||||||||||
247.60 | 2030 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 247.60 | € 247.60 | ||||||||||||
Outstanding stock options | 31,200 | 31,200 | ||||||||||||
247.60 | 2025/2030 | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Exercise price per stock options | € / shares | € 247.60 | € 247.60 | ||||||||||||
Outstanding stock options | 908,362 | 908,362 | ||||||||||||
Maximum | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Time period for beneficiaries to choose contractual term | 10 years | 10 years | ||||||||||||
Option life (in years) | Y | 6.68 | 6.68 | 6.68 | 6.68 | 6.5 | 6.68 | ||||||||
Minimum | ||||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | ||||||||||||||
Time period for beneficiaries to choose contractual term | 5 years | 5 years | ||||||||||||
Option life (in years) | Y | 6.15 | 4 | 4 | 4 | 4 |
Share-based payments - Rollforw
Share-based payments - Rollforward (Details) | 1 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2020EquityInstruments€ / shares | Oct. 31, 2020EquityInstruments | Jun. 30, 2020EquityInstruments | Apr. 30, 2020EquityInstruments | Dec. 31, 2019EquityInstruments€ / shares | Nov. 30, 2019EquityInstruments | Jun. 30, 2019EquityInstruments | Dec. 31, 2018EquityInstruments€ / shares | Jun. 30, 2018EquityInstruments | Dec. 31, 2020EquityInstruments€ / shares | Dec. 31, 2019EquityInstruments€ / shares | Dec. 31, 2018EquityInstruments€ / shares | |
Number of stock options | ||||||||||||
Total options at beginning of year | EquityInstruments | 4,358,069 | 3,536,651 | 2,862,216 | |||||||||
Granted | EquityInstruments | 908,362 | 196,500 | 550,090 | 142,700 | 921,885 | 19,800 | 423,487 | 861,575 | 178,900 | 1,797,652 | 1,365,172 | 1,040,475 |
Exercised | EquityInstruments | (602,463) | (419,317) | (319,671) | |||||||||
Forfeited | EquityInstruments | (187,515) | (124,437) | (46,369) | |||||||||
Total options at end of year | EquityInstruments | 5,365,743 | 4,358,069 | 3,536,651 | 5,365,743 | 4,358,069 | 3,536,651 | ||||||
Exercisable | EquityInstruments | 2,833,680 | 2,203,476 | 1,859,315 | 2,833,680 | 2,203,476 | 1,859,315 | ||||||
Weighted average exercise price | ||||||||||||
Beginning balance | € 63.75 | € 33.42 | € 11.54 | |||||||||
Granted | 217.35 | 128.52 | 85.37 | |||||||||
Exercised | 31.67 | 11.35 | 7.02 | |||||||||
Forfeited | 139.34 | 88.92 | 30.44 | |||||||||
Ending balance | € 116.43 | € 63.75 | € 33.42 | 116.43 | 63.75 | 33.42 | ||||||
Exercisable | € 53.17 | € 22.59 | € 9.62 | 53.17 | 22.59 | 9.62 | ||||||
Weighted average share price | € 207.43 | € 110.99 | € 66.93 | |||||||||
Weighted average remaining contractual life | 7 years 29 days | 7 years 3 months 7 days | 7 years 9 months 26 days |
Share-based payments - Range of
Share-based payments - Range of exercise price (Details) | 12 Months Ended | ||||||||||
Dec. 31, 2020EquityInstruments$ / shares | Dec. 31, 2019EquityInstruments€ / shares | Dec. 31, 2018EquityInstruments€ / shares | Dec. 31, 2020EquityInstruments€ / shares | Oct. 31, 2020€ / shares | Jun. 30, 2020€ / shares | Apr. 30, 2020€ / shares | Nov. 30, 2019€ / shares | Jun. 30, 2019€ / shares | Jun. 30, 2018€ / shares | Dec. 31, 2017EquityInstruments | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | € / shares | € 135.75 | € 86.32 | € 247.6 | € 200.22 | € 196.15 | € 119.53 | € 113.49 | € 113.49 | € 80.82 | ||
Number of share options outstanding in share-based payment arrangement | EquityInstruments | 5,365,743 | 4,358,069 | 3,536,651 | 5,365,743 | 2,862,216 | ||||||
Weighted average remaining contractual life | 7 years 29 days | 7 years 3 months 7 days | 7 years 9 months 26 days | ||||||||
2.44-3.95 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 272,017 | 272,017 | |||||||||
Weighted average remaining contractual life | 3 years 29 days | ||||||||||
7.17-9.47 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 408,399 | 408,399 | |||||||||
Weighted average remaining contractual life | 4 years 2 months 27 days | ||||||||||
10.34-14.13 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 371,128 | 371,128 | |||||||||
Weighted average remaining contractual life | 5 years 7 months 13 days | ||||||||||
18.41-21.17 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 563,180 | 563,180 | |||||||||
Weighted average remaining contractual life | 6 years 10 months 13 days | ||||||||||
80.82-86.32 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 841,587 | 841,587 | |||||||||
Weighted average remaining contractual life | 5 years 5 months 16 days | ||||||||||
113.49-135.75 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 1,305,650 | 1,305,650 | |||||||||
Weighted average remaining contractual life | 7 years 7 months 21 days | ||||||||||
196.15 - 247.60 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Number of share options outstanding in share-based payment arrangement | 1,603,782 | 1,603,782 | |||||||||
Weighted average remaining contractual life | 9 years 3 months 15 days | ||||||||||
Minimum | 2.44-3.95 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | $ 2.44 | ||||||||||
Minimum | 7.17-9.47 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 7.17 | ||||||||||
Minimum | 10.34-14.13 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 10.34 | ||||||||||
Minimum | 18.41-21.17 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 18.41 | ||||||||||
Minimum | 80.82-86.32 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 80.82 | ||||||||||
Minimum | 113.49-135.75 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 113.49 | ||||||||||
Minimum | 196.15 - 247.60 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 196.15 | ||||||||||
Maximum | 2.44-3.95 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 3.95 | ||||||||||
Maximum | 7.17-9.47 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 9.47 | ||||||||||
Maximum | 10.34-14.13 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 14.13 | ||||||||||
Maximum | 18.41-21.17 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 21.17 | ||||||||||
Maximum | 80.82-86.32 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 86.32 | ||||||||||
Maximum | 113.49-135.75 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | 135.75 | ||||||||||
Maximum | 196.15 - 247.60 | |||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||
Exercise price | $ 247.60 |
Share-based payments - Overview
Share-based payments - Overview (Details) | 1 Months Ended | 12 Months Ended | |||||||||||
Dec. 31, 2020EUR (€)EquityInstrumentsY€ / shares | Oct. 31, 2020EquityInstrumentsY€ / shares | Jun. 30, 2020EquityInstrumentsY€ / shares | Apr. 30, 2020EquityInstrumentsY€ / shares | Dec. 31, 2019EUR (€)EquityInstrumentsY€ / shares | Nov. 30, 2019EUR (€)EquityInstrumentsY€ / shares | Jun. 30, 2019EUR (€)EquityInstrumentsY€ / shares | Dec. 31, 2018EUR (€)EquityInstrumentsY€ / shares | Jun. 30, 2018EUR (€)EquityInstrumentsY€ / shares | Dec. 31, 2020EUR (€)EquityInstrumentsY€ / shares | Dec. 31, 2019EUR (€)EquityInstruments€ / shares | Dec. 31, 2018EUR (€)EquityInstruments€ / shares | Dec. 31, 2017EquityInstruments | |
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Number of options granted | EquityInstruments | 908,362 | 196,500 | 550,090 | 142,700 | 921,885 | 19,800 | 423,487 | 861,575 | 178,900 | 1,797,652 | 1,365,172 | 1,040,475 | |
Average Fair value of options | € 57.69 | € 63.45 | € 39.85 | € 32.12 | € 39.85 | ||||||||
Share price | € / shares | € 247.40 | € 126.40 | € 123.20 | € 82.20 | € 72 | ||||||||
Exercise price | € / shares | € 247.6 | € 200.22 | € 196.15 | € 119.53 | € 135.75 | € 113.49 | € 113.49 | € 86.32 | € 80.82 | € 247.6 | € 135.75 | € 86.32 | |
Expected volatility | 44.14% | 45.25% | 46.19% | 45.50% | |||||||||
Average Expected option life (in years) | Y | 6.50 | 8.59 | 7.83 | 7.36 | |||||||||
Risk-free interest rate | 0.05% | 0.07% | 0.77% | 0.72% | |||||||||
Number of share options outstanding in share-based payment arrangement | EquityInstruments | 5,365,743 | 4,358,069 | 3,536,651 | 5,365,743 | 4,358,069 | 3,536,651 | 2,862,216 | ||||||
Time period for beneficiaries to choose contractual term | 60 days | ||||||||||||
Total fair value of grant | € 57.69 | € 63.45 | € 39.85 | € 32.12 | € 39.85 | ||||||||
Share options granted (as a percent) | 100.00% | ||||||||||||
Total share based payment expense | € 84,500,000 | € 39,600,000 | € 19,200,000 | ||||||||||
Minimum | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Average fair value per share option | € / shares | € 119.26 | 74.24 | 68.01 | 62.31 | |||||||||
Average Fair value of options | € 84,500,000 | € 41.40 | € 84,500,000 | 41.40 | |||||||||
Share price | € / shares | € 209 | € 183.20 | € 126.50 | € 130.1 | |||||||||
Expected volatility | 53.00% | 44.17% | 43.46% | 44.44% | 43.80% | ||||||||
Average Expected option life (in years) | Y | 6.15 | 4 | 4 | 4 | 4 | ||||||||
Risk-free interest rate | 0.42% | 0.51% | 0.43% | 0.32% | 0.57% | ||||||||
Time period for beneficiaries to choose contractual term | 5 years | 5 years | |||||||||||
Total fair value of grant | € 84,500,000 | € 41.40 | € 84,500,000 | 41.40 | |||||||||
Maximum | |||||||||||||
Disclosure of terms and conditions of share-based payment arrangement [line items] | |||||||||||||
Average fair value per share option | € / shares | € 124.67 | € 127.68 | € 105.65 | € 120.63 | |||||||||
Average Fair value of options | € 110,300,000 | € 66.39 | € 110,300,000 | 66.39 | |||||||||
Share price | € / shares | € 239.20 | € 229.20 | € 205.60 | € 150.7 | |||||||||
Expected volatility | 53.51% | 52.71% | 52.19% | 64.77% | 44.11% | ||||||||
Average Expected option life (in years) | Y | 6.68 | 6.68 | 6.68 | 6.68 | 6.5 | 6.68 | |||||||
Risk-free interest rate | 0.40% | 0.34% | 0.28% | 0.18% | 0.24% | ||||||||
Time period for beneficiaries to choose contractual term | 10 years | 10 years | |||||||||||
Total fair value of grant | € 110,300,000 | € 66.39 | € 110,300,000 | € 66.39 |
Trade and other payables (Detai
Trade and other payables (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of subsidiaries [line items] | |||
Trade payables | € 168,140 | € 58,429 | € 24,152 |
Short-term employee benefits accruals | 56,122 | 26,872 | 12,920 |
Trade and other current payables | 224,262 | € 85,301 | € 37,072 |
Clinical Manufacturing Organizations | |||
Disclosure of subsidiaries [line items] | |||
Accruals | € 52,600 |
Revenue (Details)
Revenue (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | € 30,348 | € 22,360 | € 8,635 |
Milestone revenue recognition | 3,021 | 28,085 | 11,440 |
Research and development service fees (FTE) | 3,056 | 19,338 | 1,407 |
Total revenue | 36,425 | 69,783 | 21,482 |
Janssen | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | 29,818 | 20,056 | |
Milestone revenue recognition | 2,333 | 1,569 | |
Research and development service fees (FTE) | 2,807 | 18,968 | |
AbbVie | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | 497 | 761 | 8,455 |
Milestone revenue recognition | 671 | 26,494 | 10,510 |
AgomAb | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | 1,499 | ||
Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | 33 | 44 | 180 |
Milestone revenue recognition | 17 | 22 | 930 |
Research and development service fees (FTE) | € 249 | € 370 | € 1,407 |
Revenue - Changes In Deferred R
Revenue - Changes In Deferred Revenue (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Deferred revenue | € 290,371 | € 2,161 | € 12,720 |
Upfront payments | 288,060 | ||
Milestone payments | 49,095 | 9,516 | |
Upfront Revenue Recognition | 20,861 | ||
Upfront revenue recognition | 30,348 | 22,360 | 8,635 |
Milestone revenue recognition | 3,021 | 28,085 | 11,440 |
Deferred revenue | 257,001 | 290,371 | 2,161 |
Janssen | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Deferred revenue | 288,971 | ||
Upfront payments | 288,060 | ||
Milestone payments | 22,535 | ||
Upfront revenue recognition | 29,818 | 20,056 | |
Milestone revenue recognition | 2,333 | 1,569 | |
Deferred revenue | 256,819 | 288,971 | |
AbbVie | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Deferred revenue | 1,350 | 2,045 | 12,376 |
Milestone payments | 26,560 | 8,633 | |
Upfront revenue recognition | 497 | 761 | 8,455 |
Milestone revenue recognition | 671 | 26,494 | 10,510 |
Deferred revenue | 182 | 1,350 | 2,045 |
AgomAb | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Upfront revenue recognition | 1,499 | ||
Other | |||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||
Deferred revenue | 50 | 116 | 344 |
Milestone payments | 883 | ||
Upfront revenue recognition | 33 | 44 | 180 |
Milestone revenue recognition | 17 | 22 | 930 |
Deferred revenue | € 0 | € 50 | € 116 |
Revenue - Additional Informatio
Revenue - Additional Information (Details) € / shares in Units, € in Thousands, $ in Millions | 1 Months Ended | 12 Months Ended | |||||
Aug. 31, 2018USD ($) | Apr. 30, 2016EUR (€)item | Apr. 30, 2016USD ($)item | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€)€ / sharesshares | Dec. 31, 2018USD ($)shares | |
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Upfront payments | € 288,060 | ||||||
Milestone payments | 49,095 | € 9,516 | |||||
Amount of preclinical first milestone payment received | $ | $ 30 | ||||||
Issue of equity | € 731,546 | 678,936 | € 255,721 | ||||
Janssen | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Upfront payments | 288,060 | ||||||
Milestone payments | 22,535 | ||||||
Janssen | Collaboration and license agreement | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Milestone payments | 25,000 | ||||||
Milestone payment to be received | € 1,300 | ||||||
Percentage share of royalties | 50.00% | ||||||
Upfront payment committed | $ | $ 500 | ||||||
License payment committed | $ | 300 | ||||||
Issue of equity | $ | $ 200 | ||||||
Shares issued | shares | 1,766,899 | 1,766,899 | |||||
Share price | € / shares | € 100.02 | ||||||
AbbVie | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Milestone payments | € 26,560 | € 8,633 | |||||
Other | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Milestone payments | € 883 | ||||||
AbbVie | |||||||
Disclosure of disaggregation of revenue from contracts with customers [line items] | |||||||
Upfront, non-refundable, non-creditable payment received | € 35,100 | $ 40 | |||||
Amount of preclinical first milestone payment received | € 8,900 | $ 10 | |||||
Number of preclinical milestones achieved | item | 2 | 2 | |||||
Amount of preclinical second milestone payment received | € 8,700 | ||||||
Maximum additional development milestone payments | $ | 110 | ||||||
Maximum additional regulatory milestone payments | $ | 190 | ||||||
Maximum additional commercial milestone payments | $ | $ 325 | ||||||
Term of additional GARP-related research funding | 2 years |
Other operating income (Details
Other operating income (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Other operating income | |||
Grants | € 1,226 | € 2,289 | € 1,842 |
Research and development incentives | 8,875 | 4,818 | 2,151 |
Payroll tax rebates | 8,008 | 5,694 | 3,756 |
Total | € 18,109 | € 12,801 | € 7,749 |
Other operating income - Grants
Other operating income - Grants (Details) | Dec. 31, 2020item |
Other operating income | |
Number of conditions related to government grants that are unfulfilled | 0 |
Other operating income - Other
Other operating income - Other Incentives (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Other operating income | |||
Research and development incentives | € 8,875 | € 4,818 | € 2,151 |
Incentive refund period | 5 years | ||
Payroll tax rebates | € 8,008 | € 5,694 | € 3,756 |
Segment reporting (Details)
Segment reporting (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of geographical areas [line items] | |||
Revenue from external customers | € 36,425 | € 69,783 | € 21,482 |
Denmark | |||
Disclosure of geographical areas [line items] | |||
Revenue from external customers | 299 | 436 | 1,136 |
Belgium | |||
Disclosure of geographical areas [line items] | |||
Revenue from external customers | 1,499 | ||
United States | |||
Disclosure of geographical areas [line items] | |||
Revenue from external customers | € 36,126 | € 67,848 | 18,964 |
Other | |||
Disclosure of geographical areas [line items] | |||
Revenue from external customers | € 1,382 |
Segment reporting - Noncurrent
Segment reporting - Noncurrent assets (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Disclosure of geographical areas [line items] | |||
Non current Assets exclude deferred tax assets | € 169,127 | € 60,120 | € 6,015 |
Netherlands | |||
Disclosure of geographical areas [line items] | |||
Non current Assets exclude deferred tax assets | 1 | 1 | 1 |
Belgium | |||
Disclosure of geographical areas [line items] | |||
Non current Assets exclude deferred tax assets | 163,224 | 56,777 | 5,967 |
United States | |||
Disclosure of geographical areas [line items] | |||
Non current Assets exclude deferred tax assets | 3,872 | 3,058 | € 47 |
Japan | |||
Disclosure of geographical areas [line items] | |||
Non current Assets exclude deferred tax assets | € 2,030 | € 284 |
Research and development expe_3
Research and development expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Research and development expenses | |||
Personnel expenses | € 75,121 | € 45,733 | € 26,519 |
External research and development expenses | 228,438 | 137,050 | 48,859 |
Materials and consumables | 3,099 | 2,027 | 1,464 |
Depreciation and amortization | 2,472 | 1,641 | 494 |
Other expenses | 16,349 | 11,214 | 6,273 |
Research and development expenses | € 325,479 | € 197,665 | € 83,609 |
Selling, general and administ_3
Selling, general and administrative expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Selling, general and administrative expenses | |||
Personnel expenses | € 94,251 | € 40,082 | € 18,292 |
Consulting fees | 42,459 | 16,343 | 5,472 |
Supervisory board | 4,243 | 2,792 | 1,088 |
Other Expenses | 8,414 | 5,352 | 2,619 |
Total | € 149,367 | € 64,569 | € 27,471 |
Personnel expenses (Details)
Personnel expenses (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Personnel expenses | |||
Short-term employee benefits - Salaries | € 65,516 | € 32,866 | € 18,617 |
Short-term employee benefits - Social Security | 7,848 | 3,555 | 2,213 |
Post-employment benefits | 1,072 | 748 | 441 |
Termination benefits | 849 | 644 | 96 |
Share-based payment | 80,644 | 37,208 | 18,527 |
Employer social security contributions stock options | 13,443 | 10,794 | 4,918 |
Total employee benefits expense | € 169,372 | € 85,815 | € 44,812 |
Personnel expenses - FTE (Detai
Personnel expenses - FTE (Details) - employee | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Personnel expenses | |||
Research and development | 213 | 121.6 | 76.1 |
Selling, general and administrative | 119.5 | 56.3 | 27.6 |
Number of FTE | 332.5 | 177.9 | 103.7 |
Leases - Financial position rel
Leases - Financial position relating to leases (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | |
Disclosure of quantitative information about right-of-use assets [line items] | |||
Right-of-use assets | € 7,760 | € 6,563 | |
Additions to right-of-use assets | 3,600 | ||
Lease liabilities | |||
Lease liabilities — current | 2,833 | 1,974 | € 1,078 |
Lease liabilities- non-current | 5,035 | 4,540 | 1,712 |
Lease liabilities | 7,868 | 6,514 | € 2,790 |
Buildings | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Right-of-use assets | 6,313 | 5,576 | |
Vehicles | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Right-of-use assets | 1,233 | 744 | |
Lease equipment | |||
Disclosure of quantitative information about right-of-use assets [line items] | |||
Right-of-use assets | € 215 | € 243 |
Leases - Total contractual cash
Leases - Total contractual cash flow carrying amount (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Disclosure of maturity analysis of finance lease payments receivable [line items] | |||
Total contractual cash flow | € 8,299 | ||
Lease liabilities | 7,868 | € 6,514 | € 2,790 |
Less than 1 year | |||
Disclosure of maturity analysis of finance lease payments receivable [line items] | |||
Total contractual cash flow | 3,043 | ||
1-3 years | |||
Disclosure of maturity analysis of finance lease payments receivable [line items] | |||
Total contractual cash flow | 4,085 | ||
3-5 years | |||
Disclosure of maturity analysis of finance lease payments receivable [line items] | |||
Total contractual cash flow | € 1,171 |
Leases - Statement of profit or
Leases - Statement of profit or loss and other comprehensive income (Details) - EUR (€) € in Thousands | Jan. 01, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Financial position relating to leases | ||||
Depreciation, right-of-use assets | € 2,395 | € 1,576 | € 11 | |
Interest expense (included in finance cost) | 176 | 105 | ||
Expense relating to short-term leases | € 88 | 231 | 123 | |
Expense relating to leases of low-value assets that are not shown above as short-term leases | 5 | 5 | ||
Cash outflow for leases | 2,600 | |||
Buildings | ||||
Financial position relating to leases | ||||
Depreciation, right-of-use assets | 1,981 | 1,315 | ||
Vehicles | ||||
Financial position relating to leases | ||||
Depreciation, right-of-use assets | 386 | 233 | ||
Lease equipment | ||||
Financial position relating to leases | ||||
Depreciation, right-of-use assets | € 28 | € 28 | € 11 |
Financial result and exchange_3
Financial result and exchange gains/(losses) (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Financial result and exchange gains/(losses) | |||
Interest income | € 4,517 | € 7,874 | € 1,371 |
Net gain on current financial assets held at fair value through profit or loss and cash equivalents | 1,173 | 6,525 | 2,323 |
Financial income | 5,690 | 14,399 | 3,694 |
Net loss on current financial assets held at fair value through profit or loss and cash equivalents | (6,755) | ||
Other financial expense | (349) | (124) | |
Financial expense | (7,104) | (124) | |
Realized exchange gains/(losses) | (400) | (338) | 1,355 |
Unrealized exchange gains/(losses) | (106,556) | 6,404 | 10,953 |
Exchange gains/(losses) | € (106,956) | € 6,066 | € 12,308 |
Income tax expense (Details)
Income tax expense (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income tax expense | |||
Loss before taxes | € (526,139) | € (158,213) | € (65,847) |
Income tax calculated at 25% | 131,535 | 39,553 | 16,462 |
Effect of expenses are not deductible in determining taxable results | (11,478) | (7,701) | (3,934) |
Effect of stock issue expenses that are not deductible in determining taxable results | 11,775 | 5,750 | 3,716 |
Effect of concessions | 6,804 | 572 | 430 |
Effect of tax losses carried forward not recognized | 100,771 | 11,670 | 5,511 |
Effect of different tax rates in jurisdictions in which the company operates | (168) | (52) | (15) |
Deferred tax asset other than loss carryforwards not recognized | (39,516) | (27,341) | (11,968) |
(Underprovided)/overprovided in prior years | (857) | (3,876) | |
Other | (108) | 13 | 26 |
Income tax expense recognized in the consolidated statement of profit and loss | € (2,784) | € (4,752) | € (794) |
Income tax expense - Deferred t
Income tax expense - Deferred tax assets (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income tax expense - Deferred tax assets | |||
Unrecognized deferred tax assets | € 12,255 | ||
Unused tax losses for which no deferred tax asset recognized | 567,800 | € 160,000 | |
Unused tax loss carried forward, which will expire in 2028 | 1,400 | ||
Unused tax loss carried forward, which will expire in 2029 | € 7,200 | ||
Tax rate applicable | 25.00% | 25.00% | 25.00% |
Temporary differences and unused tax losses | |||
Income tax expense - Deferred tax assets | |||
Unrecognized deferred tax assets | € 141,900 | € 40,000 | |
Netherlands | |||
Income tax expense - Deferred tax assets | |||
Tax rate applicable | 25.00% | 25.00% | 25.00% |
Belgium | |||
Income tax expense - Deferred tax assets | |||
Tax rate applicable | 25.00% |
Income Tax Expense - Tax Expens
Income Tax Expense - Tax Expense (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income tax expense | |||
Current year | € 6,871 | € 4,752 | € 794 |
Income tax prior years | 1,547 | ||
Current tax expense | 8,418 | 4,752 | 794 |
Originating and reversal of temporary differences | (5,634) | ||
Deferred tax expense / (income) | (5,634) | ||
Total tax expense (income) | € 2,784 | € 4,752 | € 794 |
Loss per share (Details)
Loss per share (Details) - EUR (€) € / shares in Units, € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Loss per share | |||
Loss of the year | € (528,923) | € (162,965) | € (66,641) |
Weighted average number of shares outstanding | 45,410,442 | 38,619,121 | 33,419,356 |
Basic and diluted loss per share | € (11.65) | € (4.22) | € (1.99) |
Financial risk management (Deta
Financial risk management (Details) - EUR (€) € in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 |
Amortised cost | Trade and other payables | |||
Disclosure of financial assets [line items] | |||
Carrying amount of liabilities under IAS 39 | € 224,262 | € 85,301 | |
Carrying amount of liabilities under IFRS 9 | € 37,072 | ||
FVTPL | Financial assets — non-current | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 5,140 | 2,596 | |
Carrying amount of assets under IFRS 9 | 1 | ||
FVTPL | Financial assets—current | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 635,359 | 1,004,539 | |
Carrying amount of assets under IFRS 9 | 283,529 | ||
FVTPL | Cash equivalents | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 699,447 | ||
Amortised cost | Research and development incentive receivables — non-current member | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 16,840 | 8,566 | |
Carrying amount of assets under IFRS 9 | 4,883 | ||
Amortised cost | Restricted cash — non-current | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 1,243 | 630 | |
Carrying amount of assets under IFRS 9 | 251 | ||
Amortised cost | Trade and other receivables | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 5,687 | 28,115 | |
Carrying amount of assets under IFRS 9 | 2,886 | ||
Amortised cost | Research and development incentive receivables — current | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 377 | 261 | |
Carrying amount of assets under IFRS 9 | 301 | ||
Amortised cost | Restricted cash — current | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IFRS 9 | 1,692 | ||
Amortised cost | Cash and cash equivalents | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | 242,161 | 103,731 | |
Carrying amount of assets under IFRS 9 | 63,589 | ||
Amortised cost | Cash equivalents | |||
Disclosure of financial assets [line items] | |||
Carrying amount of assets under IAS 39 | € 50,001 | € 227,551 | |
Carrying amount of assets under IFRS 9 | € 217,451 |
Financial risk management - Fai
Financial risk management - Fair value (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Fair value hierarchy | |||
Transfers out of Level 1 to Level 2 assets | € 0 | ||
Transfers out of Level 1 to Level 2 liabilities | 0 | ||
Transfers out of Level 2 to Level 1 assets | 0 | ||
Transfers out of Level 2 to Level 1 liabilities | 0 | ||
Transfer into level 3 assets | 0 | ||
Transfer out of level 3 assets | 0 | ||
Transfer into level 3 liabilities | 0 | ||
Transfer out of level 3 liabilities | 0 | ||
Level 1 | |||
Fair value hierarchy | |||
Current financial assets | 635,359 | € 1,004,539 | € 283,529 |
Cash Equivalents | 699,447 | ||
Assets carried at fair value | 1,334,806 | 1,004,539 | 283,529 |
Level 3 | |||
Fair value hierarchy | |||
Non-current financial assets | 5,140 | 2,596 | 1 |
Assets carried at fair value | € 5,140 | € 2,596 | € 1 |
Financial risk management - Cap
Financial risk management - Capital risk (Details) € in Thousands, $ in Millions | Dec. 31, 2020EUR (€) | Dec. 31, 2020USD ($) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) | Dec. 31, 2017EUR (€) |
Financial risk management | |||||
Cash and cash equivalents | € 991,609 | $ 576.1 | € 331,282 | € 281,040 | € 190,867 |
Total capital | € 2,062,900 |
Financial risk management - Cre
Financial risk management - Credit risk (Details) | 12 Months Ended |
Dec. 31, 2020 | |
Credit risk | Maximum | |
Disclosure of financial assets that are either past due or impaired [line items] | |
Recommended maturity term for short term investment | 6 months |
Financial risk management - Int
Financial risk management - Interest rate risk (Details) - Interest rate risk - EUR (€) € in Millions | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Increase decrease in basis points | 25.00% | ||
Positive/negative impact | € 1.5 | € 2 | € 0.3 |
Financial risk management - For
Financial risk management - Foreign exchange risk (Details) - Currency risk - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
USD | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Net exposure to exchange differences of the monetary assets | € 1,053,803 | € 821,916 | € 312,831 |
Percentage of reasonably possible increase in risk assumption | 10.00% | ||
Percentage of reasonably possible decrease in risk assumption | 10.00% | ||
Increase (decrease) in financial instrument due to reasonably possible increase in designated risk component | € (95,800) | (74,720) | (28,440) |
Increase (decrease) in financial instrument due to reasonably possible decrease in designated risk component | 95,800 | 74,720 | 28,440 |
JPY | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Net exposure to exchange differences of the monetary assets | 215 | 488 | |
GBP | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Net exposure to exchange differences of the monetary assets | 39 | 4 | 2 |
CHF | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Net exposure to exchange differences of the monetary assets | € 94 | € 1 | € 4 |
Other currencies | |||
Disclosure of risk management strategy related to hedge accounting [line items] | |||
Percentage of reasonably possible increase in risk assumption | 10.00% | ||
Percentage of reasonably possible decrease in risk assumption | 10.00% | ||
Increase (decrease) in financial instrument due to reasonably possible increase in designated risk component | € 0 | ||
Increase (decrease) in financial instrument due to reasonably possible decrease in designated risk component | € 0 |
Related party transactions - Co
Related party transactions - Compensation (Details) € in Thousands | 1 Months Ended | 12 Months Ended | ||||||||||
Dec. 31, 2020EquityInstruments | Oct. 31, 2020EquityInstruments | Jun. 30, 2020EquityInstruments | Apr. 30, 2020EquityInstruments | Dec. 31, 2019EquityInstruments | Nov. 30, 2019EquityInstruments | Jun. 30, 2019EquityInstruments | Dec. 31, 2018EquityInstruments | Jun. 30, 2018EquityInstruments | Dec. 31, 2020EUR (€)EquityInstruments | Dec. 31, 2019EUR (€)EquityInstruments | Dec. 31, 2018EUR (€)EquityInstruments | |
Compensation of key management personnel | ||||||||||||
Gross salary | € 2,842 | € 2,527 | € 2,505 | |||||||||
Variable pay | 1,322 | 975 | 1,078 | |||||||||
Employer social security | 659 | 813 | 528 | |||||||||
Other short term benefits | 137 | 122 | 125 | |||||||||
Termination benefits | 337 | 470 | ||||||||||
Post-employment benefits for executive team members as a group | 141 | 144 | 153 | |||||||||
Employer social security contributions stock options | € 9,811 | € 9,160 | € 2,793 | |||||||||
Number of share options granted in share-based payment arrangement | EquityInstruments | 908,362 | 196,500 | 550,090 | 142,700 | 921,885 | 19,800 | 423,487 | 861,575 | 178,900 | 1,797,652 | 1,365,172 | 1,040,475 |
Non-executive Directors | ||||||||||||
Compensation of key management personnel | ||||||||||||
Total cost of stock options granted in the year | € 8,384 | € 4,330 | € 3,271 | |||||||||
Board fees and other short-term benefits for directors | 355 | 378 | 355 | |||||||||
Total benefits excluding stock options | € 8,739 | € 4,708 | € 3,626 | |||||||||
Number of share options granted in share-based payment arrangement | EquityInstruments | 70,000 | 70,000 | 85,000 | |||||||||
Executive Directors | ||||||||||||
Compensation of key management personnel | ||||||||||||
Post-employment benefits for executive team members as a group | € 52,742 | € 36,058 | € 20,544 | |||||||||
Total cost of stock options granted in the year | € 37,493 | € 21,847 | € 13,363 | |||||||||
Number of share options granted in share-based payment arrangement | EquityInstruments | 334,900 | 405,000 | 460,700 |
Commitments (Details)
Commitments (Details) € in Thousands, $ in Millions | Feb. 28, 2019USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Dec. 31, 2020EUR (€) |
Commitments [Line Items] | ||||
Commitments to acquire property, plant and equipment | € | € 0 | |||
Commitments to acquire additional intangible assets | € | 0 | |||
Contractual period | 6 months | |||
Efgartigimod | ||||
Commitments [Line Items] | ||||
Outstanding commitment | € | € 114,000 | |||
Halozyme | Global Collaboration and License Agreement | ||||
Commitments [Line Items] | ||||
Payment for each future target | $ 12.5 | |||
Future milestone payments | 160 | |||
Payment for additional milestones | $ 40 | |||
Development milestone payment | $ 10 | |||
Phase 1 milestone payment | $ 5 | |||
Phase 3 milestone payment | $ 15 |
Commitments - Future Cash Outfl
Commitments - Future Cash Outflows (Details) € in Thousands | Dec. 31, 2020EUR (€) |
Commitments [Line Items] | |
Lease commitments not commenced | € 16,912 |
1-3 years | |
Commitments [Line Items] | |
Lease commitments not commenced | 282 |
3-5 years | |
Commitments [Line Items] | |
Lease commitments not commenced | 3,382 |
More than 5 years | |
Commitments [Line Items] | |
Lease commitments not commenced | € 13,247 |
Audit Fees (Details)
Audit Fees (Details) - EUR (€) € in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Audit fees | |||
Audit fees(1) | € 808 | € 730 | € 648 |
Audit-related fees | 165 | 159 | 143 |
Total | € 973 | € 889 | € 791 |
Overview of consolidation sco_3
Overview of consolidation scope (Details) | 12 Months Ended |
Dec. 31, 2020subsidiary | |
Netherlands | |
Overview of consolidation scope | |
Participation ( as a percent) | 100.00% |
ARGENX BVBA | Belgium | |
Overview of consolidation scope | |
Number of subsidiaries | 2 |
Participation ( as a percent) | 100.00% |
ARGENX US INC | United States | |
Overview of consolidation scope | |
Number of subsidiaries | 3 |
Participation ( as a percent) | 100.00% |
ARGENX JAPAN KK | Japan | |
Overview of consolidation scope | |
Participation ( as a percent) | 100.00% |
IIP BV | Belgium | |
Overview of consolidation scope | |
Participation ( as a percent) | 100.00% |
Argenx Switzerland, SA | Switzerland | |
Overview of consolidation scope | |
Participation ( as a percent) | 100.00% |
Events after the balance shee_2
Events after the balance sheet dates (Details) $ / shares in Units, € in Thousands, $ in Millions | Feb. 05, 2021$ / sharesshares | Feb. 04, 2021EUR (€)shares | Jan. 06, 2021USD ($)$ / sharesshares | Jan. 31, 2021EUR (€) | Dec. 31, 2020EUR (€) | Dec. 31, 2019EUR (€) | Dec. 31, 2018EUR (€) |
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Proceeds from issue of new shares, gross amount | € 731,546 | € 678,936 | € 255,721 | ||||
Global Offering | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issued | shares | 3,125,000 | ||||||
Public Offering of ADR | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issued | shares | 1,608,000 | ||||||
Ifrs Share Price | $ / shares | $ 320 | ||||||
Concurrent Private Placement | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issued | shares | 1,517,000 | ||||||
Ifrs Share Price | $ / shares | $ 265.69 | ||||||
Over-Allotment Option | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Number of shares issued | shares | 468,750 | ||||||
Gross proceeds | € 954,800 | ||||||
Underwriters discount and commission | 46,800 | ||||||
Payments of stock issuance costs | 46,500 | ||||||
Proceeds from issue of new shares, gross amount | € 908,000 | ||||||
Strategic collaboration for Efgartigimod | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Upfront payment receivable | $ | $ 75 | ||||||
Number of shares issued | shares | 568,182 | ||||||
Ifrs Share Price | $ / shares | $ 132 | ||||||
Guaranteed payment | $ | $ 75 | ||||||
Additional milestone payment receivable | $ | 25 | ||||||
Strategic collaboration for Efgartigimod | Maximum | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Collaboration payments receivable | $ | $ 175 | ||||||
Binding lease commitment with Argon | |||||||
Disclosure of non-adjusting events after reporting period [line items] | |||||||
Base annual rent | € 1,700 | ||||||
Lease term | 10 years 6 months | ||||||
Rent free term | 6 months |